<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Curr Neuropharmacol</journal-id><journal-id journal-id-type="iso-abbrev">Curr Neuropharmacol</journal-id><journal-id journal-id-type="pmc-domain-id">555</journal-id><journal-id journal-id-type="pmc-domain">currneuro</journal-id><journal-id journal-id-type="publisher-id">CN</journal-id><journal-title-group><journal-title>Current Neuropharmacology</journal-title></journal-title-group><issn pub-type="ppub">1570-159X</issn><issn pub-type="epub">1875-6190</issn><publisher><publisher-name>Bentham Science Publishers</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12174946</article-id><article-id pub-id-type="pmcid-ver">PMC12174946.1</article-id><article-id pub-id-type="pmcaid">12174946</article-id><article-id pub-id-type="pmcaiid">12174946</article-id><article-id pub-id-type="pmid">39757645</article-id><article-id pub-id-type="doi">10.2174/011570159X349530241123140415</article-id><article-id pub-id-type="publisher-id">CN-23-8-929</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Medicine, Neurology, Pharmacology, Neuroscience</subject></subj-group></article-categories><title-group><article-title>Therapeutic Potential of Dexmedetomidine in Neuropsychiatric Disorders: From the Bench to the Clinic</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Hu</surname><given-names initials="X">Xiaojun</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff2" ref-type="aff">2</xref><xref rid="cor2" ref-type="corresp">#</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Luo</surname><given-names initials="R">Rong</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff2" ref-type="aff">2</xref><xref rid="cor2" ref-type="corresp">#</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lei</surname><given-names initials="F">Fan</given-names></name><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Li</surname><given-names initials="X">Xin</given-names></name><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Luo</surname><given-names initials="Y">Yuncheng</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Li</surname><given-names initials="Q">Qingran</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Yi</surname><given-names initials="L">Limei</given-names></name><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhang</surname><given-names initials="X">Xia</given-names></name><xref rid="aff3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Polyak</surname><given-names initials="A">Andrew</given-names></name><xref rid="aff4" ref-type="aff">4</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Tao</surname><given-names initials="Y">Yuanxiang</given-names></name><xref rid="aff5" ref-type="aff">5</xref><xref rid="cor1" ref-type="corresp">*</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Jiang</surname><given-names initials="R">Ruotian</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff2" ref-type="aff">2</xref><xref rid="cor1" ref-type="corresp">*</xref></contrib><aff id="aff1"><label>1</label><institution content-type="dept">Department of Anesthesiology, West China Hospital</institution>, <institution>Sichuan University</institution>, <addr-line><city>Chengdu</city>, <postal-code>610041</postal-code></addr-line>, <country country="cn">China</country>; </aff><aff id="aff2"><label>2</label><institution content-type="dept">Laboratory of Anesthesia and Critical Care Medicine, National-Local Joint Engineering Research Center of Translational Medicine of Anesthesiology, West China Hospital</institution>, <institution>Sichuan University</institution>, <addr-line><city>Chengdu</city>, <postal-code>610041</postal-code></addr-line>, <country country="cn">China</country>; </aff><aff id="aff3"><label>3</label><institution content-type="dept">Department of Neurology, West China Hospital</institution>, <institution>Sichuan University</institution>, <addr-line><city>Chengdu</city>, <postal-code>610041</postal-code></addr-line>, <country country="cn">China</country>; </aff><aff id="aff4"><label>4</label><institution content-type="dept">Rutgers Graduate School of Biomedical Sciences, Rutgers</institution>, <institution>The State University of New Jersey</institution>, <addr-line><city>New Brunswick</city>, <state>New Jersey</state>, <postal-code>07103</postal-code></addr-line>, <country country="us">USA</country>; </aff><aff id="aff5"><label>5</label><institution content-type="dept">Department of Anesthesiology, New Jersey Medical School, Rutgers</institution>, <institution>The State University of New Jersey</institution>, <addr-line><city>Newark</city>, <state>New Jersey</state>, <postal-code>07103</postal-code></addr-line>, <country country="us">USA</country></aff></contrib-group><author-notes><corresp id="cor1"><label>*</label>Address correspondence to these authors at the Department of Anesthesiology, West China Hospital, Sichuan University, Chengdu, 610041, China; Laboratory of Anesthesia and Critical Care Medicine, National-Local Joint Engineering Research Center of Translational Medicine of Anesthesiology, West China Hospital, Sichuan University, Chengdu, 610041, China; E-mail: <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ruotianjiang@scu.edu.cn">ruotianjiang@scu.edu.cn</email> (R.J.); Department of Anesthesiology, New Jersey Medical School, Rutgers, The State University of New Jersey, Newark, New Jersey, 07103, USA; E-mail: <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="yuanxiang.tao@njms.rutgers.edu">yuanxiang.tao@njms.rutgers.edu</email> (Y.T.)</corresp><corresp id="cor2"><label>#</label><italic toggle="yes">These authors contributed equally to this work.</italic></corresp></author-notes><pub-date pub-type="epub"><day>02</day><month>1</month><year>2025</year></pub-date><pub-date pub-type="ppub"><year>2025</year></pub-date><volume>23</volume><issue>8</issue><issue-id pub-id-type="pmc-issue-id">490986</issue-id><fpage>929</fpage><lpage>942</lpage><history><date date-type="received"><day>15</day><month>7</month><year>2024</year></date><date date-type="rev-recd"><day>17</day><month>9</month><year>2024</year></date><date date-type="accepted"><day>20</day><month>10</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>02</day><month>07</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>02</day><month>07</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-07-02 00:25:15.927"><day>02</day><month>07</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 The Author(s). Published by Bentham Science Publisher.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>The Author(s)</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article published under CC BY 4.0 <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/legalcode</uri></license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="CN-23-8-929.pdf"/><abstract><p>Neuropsychiatric disorders encompass a range of conditions resulting from various dysfunctions within the nervous system, manifesting in diverse neurological impairments. These disorders, including depression, schizophrenia, anxiety, and Alzheimer's disease, impose significant economic and psychological burdens on both individuals and society overall. Recent clinical and preclinical studies have highlighted that dexmedetomidine (Dex), a highly selective &#945;2 adrenergic receptor agonist, may offer therapeutic benefits beyond its well-known sedative properties. Dex has demonstrated neuroprotective effects, including anti-inflammatory and anti-apoptotic effects, as well as contributing to maintaining the integrity of the blood-brain barrier. Additionally, clinical observations suggest that Dex could be beneficial in managing neuropsychiatric disorders, with fewer side effects compared to traditional antipsychotics in both rodent and human studies. This review presents a comprehensive overview of the preclinical and clinical evidence supporting the therapeutic efficacy of Dex in neuropsychiatric disorders. We also discuss the underlying mechanisms of its effect and point out future research directions to further investigate Dex&#8217;s role in this field.</p></abstract><kwd-group kwd-group-type="author"><title>Keywords</title><kwd>Dexmedetomidine</kwd><kwd>neuroprotection</kwd><kwd>anti-inflammatory</kwd><kwd>anti-apoptotic</kwd><kwd>neuropsychiatric disorders</kwd><kwd>&#945;2 adrenergic receptor</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1"><label>1</label><title>INTRODUCTION</title><p>Neuropsychiatric disorders encompass a wide spectrum of conditions that involve both neurological and psychiatric aspects, such as Alzheimer's Disease (AD), Parkinson's Disease (PD), depressive disorders, anxiety disorders, schizophrenia, bipolar disorder, autism spectrum disorders (ASD), epilepsy, and <italic toggle="yes">etc</italic>. [<xref rid="r1" ref-type="bibr">1</xref>]. Neuropsychiatric disorders continue to impose a substantial burden on society, consistently ranking among the top ten leading causes of disability since 1990 [<xref rid="r2" ref-type="bibr">2</xref>]. Its impact extends beyond individuals, affecting families and communities, thereby representing a significant public health problem globally. However, the molecular and cellular mechanisms underlying neuropsychiatric disease remain unclear, consequently causing a lack of highly efficient and specific therapeutic management. Currently, the treatment options for neuropsychiatric disorders may have limited efficacy for specific patients, making it difficult to fully alleviate symptoms, and they often come with significant side effects. Therefore, there is an urgent need to develop novel therapeutic drugs.</p><p>Dexmedetomidine (Dex), a sedative and hypnotic medication, was initially approved by the United States FDA in 1999 as a short-acting sedative (&lt; 24 hours) for use in the Intensive Care Unit (ICU) [<xref rid="r3" ref-type="bibr">3</xref>]. By 2008, its use was extended to long-term sedation (over 24 hours) in the ICU, including for patients without tracheal intubation and those undergoing perioperative care [<xref rid="r4" ref-type="bibr">4</xref>]. Dex&#8217;s sedative effect is concentration-dependent: plasma levels between 0.2 and 0.3 ng/mL result in light sedation, allowing the patient to be easily roused, while deeper, unarousable sedation occurs at concentrations above 1.9 ng/mL [<xref rid="r5" ref-type="bibr">5</xref>, <xref rid="r6" ref-type="bibr">6</xref>]. The sedative effect of Dex very resembles natural sleep, enabling the Dex-treated patients to exhibit greater states of alertness and cooperation, as compared to those taking other sedatives, such as propofol and midazolam [<xref rid="r7" ref-type="bibr">7</xref>-<xref rid="r10" ref-type="bibr">10</xref>]. Furthermore, Dex possesses anti-inflammatory, anti-sympathetic, analgesic, and other properties, which are likely associated with the reduction in the incidence of postoperative delirium [<xref rid="r11" ref-type="bibr">11</xref>]. These characteristics make Dex quickly integrated into widespread use as a sedative.</p><p>Although Dex was first used for its sedative effects, its diverse pharmacological actions suggested that it could also be effective in neuropsychiatric disorders. In 1993, Hoffman <italic toggle="yes">et al</italic>. first reported the neuroprotective effects of Dex, demonstrating in a rat model of cerebral ischemia that pre-treatment with Dex reduced intracranial catecholamine levels and mitigated neuronal damage [<xref rid="r12" ref-type="bibr">12</xref>]. This pioneer work promoted numerous researchers to investigate the neuroprotective properties of Dex. Preclinical studies have shown that Dex exerted its neuroprotective effects by inhibiting the release of inflammatory factors, suppressing apoptotic pathways, reducing the production of pro-apoptotic proteins, and safeguarding the integrity of the blood-brain barrier in some models of nerve damage [<xref rid="r13" ref-type="bibr">13</xref>-<xref rid="r17" ref-type="bibr">17</xref>]. In clinical settings, Dex has often been used in neurosurgery, since it effectively reduces brain metabolism, protects neurons, and does not affect neurophysiological monitoring [<xref rid="r18" ref-type="bibr">18</xref>]. It has been proven that the proper use of Dex can significantly relieve perioperative anxiety [<xref rid="r19" ref-type="bibr">19</xref>, <xref rid="r20" ref-type="bibr">20</xref>]. In 2022, sublingual Dex (BXCL501) received approval for the treatment of agitation associated with schizophrenia and bipolar disorder in adult patients [<xref rid="r21" ref-type="bibr">21</xref>]. The availability of BXCL501 has expanded the clinical application of Dex, making it a valuable therapeutic option for neuropsychiatric disorders. Dex's neuroprotective effects hold promise for slowing the progression of these conditions.</p><p>This article attempts to provide a comprehensive overview of the mechanisms underlying Dex&#8217;s neuroprotective effects, with a particular emphasis on its application in neuropsychiatric disorders. Furthermore, we discuss the limitations of current research and propose directions for future investigations.</p></sec><sec sec-type="other1" id="sec2"><label>2</label><title>THE MOLECULAR AND CELLULAR MECHANISM OF ACTION OF DEX IN THE NERVOUS SYSTEM</title><p>The &#945;2 adrenergic receptors (&#945;2ARs) are subtypes of the G<sub>i/o</sub> -protein-coupled receptor family. They can be selectively activated by Dex and are considered important molecular targets for Dex to exert its effect [<xref rid="r22" ref-type="bibr">22</xref>]. These &#945;2ARs are widely distributed in the central nervous system, autonomic ganglia, and various peripheral organ tissues, including blood vessels, liver, kidney, pancreas, <italic toggle="yes">etc</italic>. [<xref rid="r23" ref-type="bibr">23</xref>].</p><p>The &#945;2ARs exist in three subtypes: &#945;2A, &#945;2B, and &#945;2C [<xref rid="r22" ref-type="bibr">22</xref>]. Among the three subtypes, &#945;2A adrenergic receptors (&#945;2A-ARs) have been extensively studied and are recognized as major presynaptic inhibitory feedback receptors, that regulate the release of norepinephrine (NE) [<xref rid="r24" ref-type="bibr">24</xref>]. Dex, as a highly selective agonist, can exert sedative and analgesic functions by activating &#945;2A-ARs to control the release of NE [<xref rid="r24" ref-type="bibr">24</xref>, <xref rid="r25" ref-type="bibr">25</xref>]. The &#945;2B adrenergic receptors (&#945;2B-ARs) are predominantly located in peripheral vascular smooth muscle and play an important role in regulating cardiovascular function [<xref rid="r26" ref-type="bibr">26</xref>, <xref rid="r27" ref-type="bibr">27</xref>]. Activation of peripheral &#945;2B-ARs causes sodium retention and peripheral vasoconstriction, indicating that &#945;2B-ARs are involved in the maintenance of hypertension [<xref rid="r27" ref-type="bibr">27</xref>, <xref rid="r28" ref-type="bibr">28</xref>]. The &#945;2C adrenergic receptors (&#945;2C-ARs) are mainly found in the hippocampus, basal ganglia, olfactory bulb system, and cerebral cortex [<xref rid="r29" ref-type="bibr">29</xref>]. Apart from modulating the release of NE, &#945;2C-ARs also play a crucial role in regulating the release of dopamine, serotonin, and other neurotransmitters, which hold a significant influence on neuropsychiatric disorders [<xref rid="r30" ref-type="bibr">30</xref>]. The involvement of &#945;2C-ARs is implicated in the regulation of intricate memory processes and the pathogenesis of neuropsychiatric conditions, including depressive disorder, AD, substance use disorder, and schizophrenia [<xref rid="r29" ref-type="bibr">29</xref>, <xref rid="r31" ref-type="bibr">31</xref>, <xref rid="r32" ref-type="bibr">32</xref>]. Pharmacological selective inhibition or transgenic knockout of &#945;2C-AR has demonstrated anxiety alleviation and potential therapeutic benefits for cognitive deficits associated with schizophrenia, depressive disorder, and other related disorders [<xref rid="r32" ref-type="bibr">32</xref>-<xref rid="r34" ref-type="bibr">34</xref>]. These &#945;2C-ARs&#8217;s functions indicate that &#945;2C-AR may be a potential target for Dex in the treatment of neuropsychiatric disorders. It should be noted that these three receptor subtypes do not function independently but rather interact in conjunction under various physiological and pathological contexts.</p><p>While &#945;2ARs are predominantly expressed in neurons, recent research indicates their presence in other cell types, including astrocytes and microglia. Studies using immunofluorescence and reverse transcriptase polymerase chain reaction (RT-PCR) confirmed &#945;2A-AR expression on astrocytes, both <italic toggle="yes">in vitro</italic> and <italic toggle="yes">in situ</italic> in mouse brains [<xref rid="r35" ref-type="bibr">35</xref>-<xref rid="r37" ref-type="bibr">37</xref>]. However, there is still a controversial opinion among researchers regarding the presence of &#945;2A-AR on microglia. An <italic toggle="yes">in vitro</italic> study demonstrated the expression of mRNA encoding the &#945;2A-AR in lipopolysaccharide-activated cultured microglia through PCR assay [<xref rid="r38" ref-type="bibr">38</xref>]. In contrast, immunofluorescence staining of brain sections from a mouse sepsis model revealed the absence of &#945;2A-AR in microglia located in the hippocampus [<xref rid="r37" ref-type="bibr">37</xref>, <xref rid="r39" ref-type="bibr">39</xref>]. The different findings among these studies may be attributed to several factors. Firstly, <italic toggle="yes">in vivo</italic> and <italic toggle="yes">in vitro</italic> experiments may yield different results. Secondly, the differences in the experimental models carried out may influence the expression of genes involved in microglial function [<xref rid="r39" ref-type="bibr">39</xref>]. Future investigations can employ additional research techniques, such as RNA scope, cell-specific PCR, and WB to further elucidate the expression of &#945;2A-AR in microglia under distinct experimental conditions.</p><p>The possibility that Dex may exert its effects by binding to &#945;2ARs on glial cells, in addition to neurons, is an emerging area of interest. Previous investigations have emphasized the involvement of glial cells in the neuroprotective effects of Dex. In animal models of neuropsychiatric disorders, such as AD and anxiety, Dex demonstrated effective inhibition of microglial overactivation, prevention of astrocyte pyroptosis, and promotion of M2 microglia polarization, leading to the reductions in pro-inflammatory factors and axon demyelination [<xref rid="r13" ref-type="bibr">13</xref>, <xref rid="r40" ref-type="bibr">40</xref>]. Consequently, these effects contribute to the amelioration of tissue damage, neuronal loss, and improvement in neurological function. However, whether Dex directly acts on &#945;2ARs in glial cells remains unclear. Gao <italic toggle="yes">et al.</italic> reported that the anti-inflammatory effects of Dex on LPS-treated microglia could be blocked by &#945;2ARs inhibitors, such as yohimbine, suggesting that Dex may interact with &#945;2ARs in glial cells [<xref rid="r41" ref-type="bibr">41</xref>]. Nonetheless, further research is required to validate this conclusion. Conditional knockout of &#945;2ARs in glial cells could provide insight into the mechanisms of Dex's action. Additionally, glial cells may participate in other effects of Dex, such as inhibiting the transitional activation of astrocytes and microglia under arthritis pain conditions and suppressing gap junction communication between astrocytes and neurons under general anesthesia [<xref rid="r42" ref-type="bibr">42</xref>, <xref rid="r43" ref-type="bibr">43</xref>]. Determining whether glial cells are essential for Dex&#8217;s effects is crucial for identifying new therapeutic targets and developing novel drugs. The main proposed mechanisms of Dex functions are described in Fig. (<bold><xref rid="F1" ref-type="fig">1</xref></bold>).</p></sec><sec sec-type="other2" id="sec3"><label>3</label><title>ROLE OF DEX IN NEUROPSYCHIATRIC DISORDERS</title><p>The neuroprotective effects of Dex have spurred a surge of interest in its potential to treat neuropsychiatric disorders. The evidence described below focuses on the mechanisms of Dex action and its clinical use in neuropsychiatric disorders. Tables <bold><xref rid="T1" ref-type="table">1</xref></bold> and <bold><xref rid="T2" ref-type="table">2</xref></bold> also summarize preclinical and clinical findings across multiple neuropsychiatric disorders.</p><sec id="sec3.1"><label>3.1</label><title>AD</title><p>In individuals with AD, there are three key neuropathological features: &#946;-amyloid (A&#946;) deposition, neurofibrillary tangles containing hyperphosphorylated tau (P-tau), and neuroinflammation [<xref rid="r44" ref-type="bibr">44</xref>-<xref rid="r47" ref-type="bibr">47</xref>]. These characteristics are interconnected and mutually reinforce each other, leading to neurotoxicity and apoptosis [<xref rid="r48" ref-type="bibr">48</xref>-<xref rid="r50" ref-type="bibr">50</xref>].</p><p>Recent preclinical studies have highlighted the potential function of Dex in slowing the progression of AD. Dex effectively inhibited neuroinflammation and prevented neuron apoptosis under AD conditions [<xref rid="r51" ref-type="bibr">51</xref>-<xref rid="r53" ref-type="bibr">53</xref>] and could also alleviate cognitive deficits, a prominent symptom of AD, in mouse models of AD, as assessed by Morris water maze and Y maze tests [<xref rid="r13" ref-type="bibr">13</xref>, <xref rid="r15" ref-type="bibr">15</xref>, <xref rid="r54" ref-type="bibr">54</xref>]. Therefore, growing research is focused on uncovering the neuroprotective mechanisms of Dex in AD.</p><p>With regards to A&#946;, Luo <italic toggle="yes">et al</italic>. discovered that Dex inhibited A&#946; deposition, while Gou <italic toggle="yes">et al</italic>. demonstrated that Dex effectively suppressed A&#946;-induced apoptosis in neuronal cells [<xref rid="r13" ref-type="bibr">13</xref>, <xref rid="r55" ref-type="bibr">55</xref>]. These effects were inhibited by &#945;2ARs antagonist, yohimbine, indicating that Dex may treat AD by acting on the &#945;2ARs [<xref rid="r13" ref-type="bibr">13</xref>]. However, yohimbine has several limitations, including low efficiency and lack of selectivity. More importantly, it is unknown which specific a2AR subtype such as the a2A-AR, a2B-AR or a2C-AR subtype is involved in the treatment of Dex for AD.</p><p>Microglial activation is considered to play a significant role in the AD-related neuroninflammation [<xref rid="r46" ref-type="bibr">46</xref>]. Dex has been found to promote phenotypic transformation of microglia from an inflammatory activated state to a no nerve-damaging function both <italic toggle="yes">in vitro</italic> and <italic toggle="yes">in vivo</italic> works by increasing the expression of triggering receptors expressed on myeloid cells 2 (TREM2). The neuroprotective role of TREM2 has been confirmed through genetic investigations in AD [<xref rid="r56" ref-type="bibr">56</xref>-<xref rid="r57" ref-type="bibr">57</xref>]. Additionally, astrocyte activation contributes to AD pathology, particularly in A&#946; deposition, though it is still unclear whether Dex directly affects astrocytes [<xref rid="r58" ref-type="bibr">58</xref>].</p><p>MicroRNAs (miRNAs), which regulate post-transcriptional gene expression, are key players in AD. They help modulate A&#946; clearance by targeting multiple mRNA molecules, making them promising therapeutic targets [<xref rid="r15" ref-type="bibr">15</xref>, <xref rid="r59" ref-type="bibr">59</xref>]. Some studies suggest that Dex can influence miRNA activity to maintain A&#946; balance, promoting its clearance while also exhibiting anti-inflammatory, anti-apoptotic, and antioxidant effects [<xref rid="r15" ref-type="bibr">15</xref>, <xref rid="r55" ref-type="bibr">55</xref>, <xref rid="r60" ref-type="bibr">60</xref>]. Exploring the potential function of Dex in targeting miRNAs could provide another promising avenue for AD treatment.</p><p>However, controversial results have been reported regarding the effects of Dex on tau phosphorylation. Tau is abnormally hyperphosphorylated and forms neurofibrillary tangles in AD, resulting in neuronal degeneration and memory disorders [<xref rid="r47" ref-type="bibr">47</xref>]. A study revealed that Dex increased tau phosphorylation and impaired spatial memory [<xref rid="r61" ref-type="bibr">61</xref>]. These conflicting findings may be attributed to variations in the dosage and duration of Dex administration. Furthermore, the increase in tau phosphorylation caused by Dex appears to be a transient change.</p><p>Currently, an FDA-approved sublingual film formulation of Dex (BXCL501) has entered phase III clinical trials for the treatment of agitation associated with AD [<xref rid="r62" ref-type="bibr">62</xref>]. Nevertheless, it remains a paucity of clinical trials investigating the use of Dex in treating cognitive and sleep disorders, and other aspects of AD. A randomized, double-blind, placebo-controlled follow-up study is necessary for the assessment of the therapeutic effects of Dex on AD.</p><p>Overall, these studies reveal a potentially important role for Dex in the treatment of AD by regulating A&#946; balance and anti-inflammation, implying that Dex may be a promising potential drug to alleviate AD progression and agitation.</p></sec><sec id="sec3.2"><label>3.2</label><title>PD</title><p>PD is a prevalent neurodegenerative disorder marked by the degeneration of dopaminergic neurons in the Substantia Nigra (SN). It is accompanied by various motor symptoms, including dyskinesia, muscle stiffness, resting tremors, and a spectrum of non-motor symptoms [<xref rid="r63" ref-type="bibr">63</xref>].</p><p>The <italic toggle="yes">in vitro</italic> experimental studies demonstrated that Dex reduced the production of Reactive Oxygen Species (ROS), regulated the cell cycle, and consequently attenuated apoptosis in all-trans-retinoicacid differentiated SH-SY5Y cells, treated with 1-methyl-4-phenylpyridinium (MPP<sup>+</sup>) for PD research [<xref rid="r14" ref-type="bibr">14</xref>]. However, it should be noted that <italic toggle="yes">in vitro</italic> experiments cannot fully replicate the complexities of the <italic toggle="yes">in vivo</italic> environment. Recent <italic toggle="yes">in vivo</italic> studies using mouse models of PD induced by methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) have demonstrated that Dex reduces the degeneration of dopaminergic neurons, suppresses inflammation, and downregulates apoptotic proteins after a 3-7 day treatment [<xref rid="r64" ref-type="bibr">64</xref>, <xref rid="r65" ref-type="bibr">65</xref>]. Furthermore, Zhou <italic toggle="yes">et al</italic>. reported that the neuronal mechanism by which Dex potentially modifies PD. They found that Dex decreased abnormal excitation in striatal neurons by reducing the excessive synaptic activity [<xref rid="r64" ref-type="bibr">64</xref>]. Notably, this effect was reversed by administrating a D2 antagonist, suggesting that Dex may exert its effects by influencing the D2 receptors. However, whether Dex directly acts on the D2 receptor requires further verification [<xref rid="r64" ref-type="bibr">64</xref>, <xref rid="r65" ref-type="bibr">65</xref>]. Prior studies have examined the impact of Dex on dopamine: Dex diminishes extracellular dopamine levels in the nucleus accumbens and modulates histone H3 acetylation <italic toggle="yes">via</italic> the ERK1/2 signaling pathway in striatal dopamine neurons [<xref rid="r66" ref-type="bibr">66</xref>, <xref rid="r67" ref-type="bibr">67</xref>]. These mechanisms likely contribute to Dex's neuroprotective properties, highlighting further investigations into the role of Dex within the dopamine system.</p><p>In clinical practice, Dex has extensive applications as a sedative in PD patients undergoing surgical procedures. In the context of PD, the management of general anesthesia presents challenges due to the impaired autonomic nervous system regulation function. These patients experience an increased cardiac burden following general anesthesia, which may potentially cause arrhythmias. Consequently, the utilization of local anesthesia and nerve blocks are often necessary to address these complexities. However, unstable autonomic activity poses a significant challenge in local anesthesia procedures. Recent case reports have shown that intraoperative sedation with Dex reduces the risk of autonomic instability, creating safer conditions for surgery [<xref rid="r68" ref-type="bibr">68</xref>-<xref rid="r70" ref-type="bibr">70</xref>]. Nevertheless, a future randomized, placebo-controlled study is necessary to determine the efficacy of Dex administration in patients with PD-related dyskinesia.</p><p>Dex also has extensive application in Deep Brain Stimulation (DBS), which is the primary treatment for advanced PD [<xref rid="r71" ref-type="bibr">71</xref>]. This surgical procedure involves implanting electrodes in specific brain regions to modulate abnormal neuronal firing patterns and alleviate motor and non-motor symptoms [<xref rid="r71" ref-type="bibr">71</xref>, <xref rid="r72" ref-type="bibr">72</xref>]. To optimize electrode placement, physicians often use microelectrode recordings (MER) during surgery, which is typically performed with the patient awake to avoid interference from anesthetics [<xref rid="r73" ref-type="bibr">73</xref>, <xref rid="r74" ref-type="bibr">74</xref>]. A recent study by Simon <italic toggle="yes">et al.</italic> demonstrated that Dex did not alter the characteristic subthalamic activity during DBS and provide good intraoperative sedation for patients. Another notable advantage of Dex was its ability to rapidly restore baseline subthalamic activity patterns in less than 10 minutes, even at a high dose of Dex [<xref rid="r75" ref-type="bibr">75</xref>]. However, it is crucial for the anesthesiologic team to diligently monitor the conscious state of the patient during this process. Furthermore, the patients who received Dex during DBS exhibited stable vital signs and did not experience significant side effects [<xref rid="r76" ref-type="bibr">76</xref>, <xref rid="r77" ref-type="bibr">77</xref>]. These findings highlight the significant potential of Dex in PD surgeries.</p><p>In recent years, there has been a growing research focus on the clinical therapeutic potential of Dex for PD. A noteworthy case report in 2020 highlighted the efficacy of Dex in treating acute delirium in PD patients [<xref rid="r78" ref-type="bibr">78</xref>]. A prospective clinical study is to investigate the therapeutic effects of Dex in elderly patients with PD [<xref rid="r79" ref-type="bibr">79</xref>]. However, despite these advancements, there is still a need for further research to comprehensively understand the broader therapeutic benefits of Dex in a clinical context for PD.</p><p>In conclusion, current data highlight the important role of Dex in both the therapeutic management and surgical treatment of PD. Its neuroprotective effects and potential to alleviate symptoms suggest that Dex may be a valuable therapeutic agent for PD.</p></sec><sec id="sec3.3"><label>3.3</label><title>Epilepsy</title><p>Epilepsy, a chronic brain disorder characterized by abnormal and recurrent neuronal activity, poses a significant health concern, leading to premature mortality [<xref rid="r80" ref-type="bibr">80</xref>]. Current research explores both treatments for epilepsy and its underlying mechanisms. Studies in rat models have shown that Dex effectively reduces seizure severity, prolongs the onset of seizures, and decreases spike frequency in pentylenetetrazole-induced seizures. In a kainic acid-induced epilepsy model, Dex also demonstrated neuroprotective effects by reducing glutamate levels, preventing hippocampal neuron apoptosis, and upregulating neuroprotective proteins such as Bcl-2, Nrf2, and brain-derived neurotrophic factor [<xref rid="r81" ref-type="bibr">81</xref>-<xref rid="r84" ref-type="bibr">84</xref>].</p><p>In comparison to clonidine, which delays amygdala kindling but is less effective at controlling seizures and can even induce proconvulsive effects at higher doses, Dex offers a dual benefit of seizure control and neuroprotection [<xref rid="r81" ref-type="bibr">81</xref>, <xref rid="r84" ref-type="bibr">84</xref>, <xref rid="r85" ref-type="bibr">85</xref>]. Dex also shows potential for early detection of latent epilepsy, as seen in the Genetic Absence Epilepsy Rat from Strasbourg (GAERS) model of absence epilepsy, where it induced spike-and-wave discharges, a key marker of idiopathic generalized epilepsies-an effect not observed in wild-type mice [<xref rid="r86" ref-type="bibr">86</xref>, <xref rid="r87" ref-type="bibr">87</xref>]. This report holds great clinical significance, as it expands the application of Dex in the clinical diagnosis and treatment of epilepsy.</p><p>In the context of epilepsy mechanisms, the dysregulation of NE is thought to play a critical role in epilepsy, with NE generally considered protective against seizures [<xref rid="r88" ref-type="bibr">88</xref>]. The &#945;2ARs, as the receptors of NE, have also garnered significant attention regarding their role in epilepsy. The activation of the &#945;2ARs receptor has been observed to inhibit epileptiform activity in the rat hippocampal CA3 region, an area associated with a high incidence of epilepsy [<xref rid="r89" ref-type="bibr">89</xref>]. Systemic administration of &#945;2ARs antagonists, such as idazoxan, yohimbine, or rauwolscine, has been shown to accelerate amygdala kindling. Mice carrying a point mutation in the LC of &#945;2ARs (the D79N mutant mice) exhibited a substantial loss of &#945;2ARs function and were notably prone to amygdala kindling [<xref rid="r88" ref-type="bibr">88</xref>]. However, the existing evidence on the antiepileptic effects of Dex suffers from a lack of cell-specific &#945;2ARs genetic tools and specific antagonist-related works. Consequently, a thorough investigation into the potential involvement of &#945;2ARs in Dex-mediated effects is still warranted. Future research directions should consider knocking out &#945;2ARs in specific brain regions and specific subtypes of &#945;2ARs to address these gaps. There is also a paradox in Dex's antiepileptic action, as it is generally thought to inhibit NE release, yet still exerts anticonvulsant effects. This may be due to the low doses used in epilepsy studies (&#8804; 100 &#181;g/kg), which may not significantly affect the LC, the brain's primary source of NE. In other words, Dex's antiepileptic efficacy might not stem from NE inhibition [<xref rid="r9" ref-type="bibr">9</xref>].</p><p>Clinically, Dex is widely used for sedation in epilepsy patients during examinations and surgery. It has proven particularly useful during magnetoencephalography (MEG) for presurgical evaluation, as it provides effective sedation with minimal impact on MEG spike frequency [<xref rid="r90" ref-type="bibr">90</xref>, <xref rid="r91" ref-type="bibr">91</xref>].</p><p>In addition to accurately identifying the epileptogenic focus preoperatively, it is also essential to locate and map the seizure focus during surgery. Intraoperative electrocorticography (ECoG) is commonly employed for this purpose. However, the inhalation anesthetics used as intraoperative agents can significantly suppress brain electrical activity, thus affecting ECoG readings [<xref rid="r92" ref-type="bibr">92</xref>]. Dex either enhanced or did not alter the spike rate during intraoperative ECoG recording in most epilepsy surgeries. This suggests that Dex may hold potential utility in epilepsy surgery [<xref rid="r92" ref-type="bibr">92</xref>].</p></sec><sec id="sec3.4"><label>3.4</label><title>Anxiety</title><p>Some studies have indicated that Dex effectively reduces anxiety-like behaviors in animal models. Jang <italic toggle="yes">et al</italic>. provided valuable insights into this concern. They established rat models of Post-Traumatic Stress Disorder (PTSD) and observed that the administration of Dex expedited the extinction of fear memories and reduced anxiety levels [<xref rid="r93" ref-type="bibr">93</xref>]. These findings suggest that Dex possesses an anti-anxiety effect independent of its sedative, analgesic, and anti-inflammatory properties.</p><p>Dex has demonstrated its efficacy in alleviating anxiety in socially frustrated mice, through the inhibition of corticotropin-releasing hormone-producing hypothalamic paraventricular neurons (CRH<sup>PVH</sup>). Manipulating the activation or inhibition of CRH<sup>PVH</sup> through chemogenetic assay was shown to modulate the anti-anxiety effects of Dex [<xref rid="r94" ref-type="bibr">94</xref>]. These findings underscore the significance of CRH<sup>PVH</sup> as a crucial target for the anti-anxiety actions of Dex. Moreover, the inhibitory effect of Dex on CRH<sup>PVH</sup> may be mediated through &#945;2ARs [<xref rid="r94" ref-type="bibr">94</xref>]. This study represents a significant advancement in understanding the mechanism underlying the anti-anxiety effects of Dex, as it identified the specific nuclei and neurons involved for the first time. However, systemic administration of yohimbine in these studies may not fully inhibit &#945;2ARs, and the specific receptor subtype and brain regions involved are still unclear. Future research should explore Dex&#8217;s anxiolytic mechanism using brain-region- and cell-type-specific &#945;2AR knockdown techniques.</p><p>Clinically, Dex has gained popularity for managing anxiety during the perioperative period, with both intravenous and intranasal administrations showing effectiveness, especially in children [<xref rid="r19" ref-type="bibr">19</xref>, <xref rid="r20" ref-type="bibr">20</xref>, <xref rid="r40" ref-type="bibr">40</xref>, <xref rid="r95" ref-type="bibr">95</xref>, <xref rid="r96" ref-type="bibr">96</xref>]. Furthermore, when compared to other drugs (such as fentanyl and midazolam) commonly used during the perioperative period, Dex appears to exhibit superior anti-anxiety effects [<xref rid="r95" ref-type="bibr">95</xref>, <xref rid="r97" ref-type="bibr">97</xref>-<xref rid="r99" ref-type="bibr">99</xref>]. However, the available evidence remains limited. Larger randomized controlled trials are necessary to establish the role of Dex as a treatment for anxiety. Additionally, current research primarily focuses on the effects of Dex in the perioperative period. Its efficacy in treating neurotic anxiety has yet to be conclusively proven.</p></sec><sec id="sec3.5"><label>3.5</label><title>Depressive Disorder</title><p>Major Depressive Disorder (MDD) is one of the most prevalent psychiatric disorders globally and stands as a leading cause of disability [<xref rid="r100" ref-type="bibr">100</xref>]. It affects approximately 7% of the population in the United States [<xref rid="r101" ref-type="bibr">101</xref>, <xref rid="r102" ref-type="bibr">102</xref>].</p><p>Numerous studies have consistently demonstrated that depressive disorder has been associated with elevated levels of NE [<xref rid="r103" ref-type="bibr">103</xref>, <xref rid="r104" ref-type="bibr">104</xref>]. Dex, known for its action on the &#945;2A-ARs in the LC, acts by inhibiting the release of NE [<xref rid="r101" ref-type="bibr">101</xref>]. This suggests that Dex may be a potentially effective treatment for depression. In 2018, Moon <italic toggle="yes">et al</italic>. first conducted a study in which they found that Dex could alleviate depression in a rat model induced by sleep deprivation [<xref rid="r105" ref-type="bibr">105</xref>]. By the use of the assessments, such as the forced swimming test and tail suspension test, an increase in immobility latency was observed in the sleep-deprived model, indicating depression. In addition, the analyses of brain tissue using WB and ELISA assays revealed decreases in dopamine receptors and tryptophan hydroxylase, along with an increase in tyrosine hydroxylase, suggesting an abnormal increase in dopamine release. The administration of low-dose intraperitoneal Dex significantly abated depression-like behavior and normalized dopamine release in sleep-deprived mice [<xref rid="r105" ref-type="bibr">105</xref>]. This study not only provided strong evidence for the antidepressant effects of Dex but also unveiled its potential influence on the dopaminergic system. Moreover, other depression models have also corroborated the antidepressant effects of Dex, demonstrating its ability to alleviate depressive symptoms induced by chronic constrictive injury through the promotion of neurogenesis in the hippocampus [<xref rid="r106" ref-type="bibr">106</xref>].</p><p>In addition, Dex possesses several advantages over other antidepressant medications. Unlike ketamine, Dex demonstrated a lesser impact on cognitive abilities, memory, and emotional function, primarily due to its protective effects on limbic regions [<xref rid="r107" ref-type="bibr">107</xref>]. Moreover, previous studies revealed that Dex could mitigate the learning and memory deficits induced by ECT in depressed rats [<xref rid="r108" ref-type="bibr">108</xref>]. These advantageous characteristics of Dex form the foundation for its potential clinical approval as an antidepressant.</p><p>In clinical practice, Dex is commonly used as an adjunctive medication in conjunction with ECT. Depressed patients who received Dex alongside ECT showed improved antidepressant effects, reduced agitation, and more stable vital signs [<xref rid="r109" ref-type="bibr">109</xref>]. Furthermore, clinical trials have indicated that postpartum administration of Dex could significantly decrease the incidence of postpartum depression. However, there is a scarcity of clinical trials specifically investigating the therapeutic effects of Dex in patients with depression [<xref rid="r110" ref-type="bibr">110</xref>, <xref rid="r111" ref-type="bibr">111</xref>].</p><p>Recently, a new study suggested that Dex might emerge as a potent alternative to ECT as an antidepressant treatment [<xref rid="r112" ref-type="bibr">112</xref>]. In this study, patients with MDD were randomly assigned to receive either Dex infusions or ECT treatment. The Dex infusion or ECT treatment was administered once every three days for a total of 10 sessions. The results revealed that Dex exhibited rapid and long-lasting antidepressant properties with fewer side effects compared to ECT [<xref rid="r112" ref-type="bibr">112</xref>].</p><p>These findings indicate that Dex holds promise as an antidepressant drug; however, further clinical trials are necessary to validate these results. Furthermore, previous investigations into the antidepressant properties of Dex predominantly employed intravenous administration. However, treating depression typically requires a prolonged course of therapy. Intravenous administration is an invasive route, posing challenges for the clinical use of Dex as an antidepressant. Notably, Dex has recently become available in sublingual form (BXCL501) and has achieved approval for the management of agitation. Future studies should focus on the effectiveness of this sublingual administration on depression and compare its efficacy to intravenous administration. Additionally, the absence of specific &#945;2ARs inhibitors and gene tools for investigating the antidepressant properties of Dex presents a limitation in current research. There remains uncertainty regarding the precise target of the antidepressant effects of Dex. Further exploring the mechanism of Dex&#8217;s action would be valuable for advancing the development of novel antidepressant medications.</p></sec><sec id="sec3.6"><label>3.6</label><title>Agitation Associated with Schizophrenia and Bipolar Disorder</title><p>Acute agitation commonly observed in emergency departments or inpatient settings is often associated with psychosis. It can escalate into aggressive behavior if acute agitation is untreated. Previous studies have predominantly focused on the preventive and alleviating effects of Dex in postoperative agitation [<xref rid="r113" ref-type="bibr">113</xref>]. However, recent studies have also demonstrated the therapeutic efficacy of Dex in managing agitation resulting more specifically from mental illness. The treatment options for acute agitation and aggression in patients with severe mental illness primarily rely on benzodiazepines and first- and second-generation antipsychotics [<xref rid="r114" ref-type="bibr">114</xref>]. Nevertheless, the significant side effects and invasive administration route of these drugs fall short of meeting current clinical requirements. Recent studies have shown that, in individuals with mild to moderate agitation related to bipolar disorder, the administration of 120 &#956;g or 180 &#956;g of BXCL501 significantly reduced agitation scores at the 2-hour mark compared to control participants [<xref rid="r115" ref-type="bibr">115</xref>].</p><p>BXCL501 offers several distinct advantages over commonly used antipsychotic medications and benzodiazepines for managing agitation. Firstly, Dex is associated with a lower incidence of side effects such as nausea, vomiting, insomnia, and extrapyramidal symptoms compared to drugs like haloperidol [<xref rid="r116" ref-type="bibr">116</xref>]. Secondly, it poses a lower risk of delirium while keeping patients easily rousable [<xref rid="r7" ref-type="bibr">7</xref>, <xref rid="r117" ref-type="bibr">117</xref>]. Additionally, sublingual administration provides a non-invasive and gentle approach, promoting patient cooperation during treatment [<xref rid="r118" ref-type="bibr">118</xref>].</p><p>The limitations exist regarding the study of Dex in the treatment of agitation. Firstly, most clinical trials have only examined its effects after a single episode. It remains unclear whether Dex can fundamentally reduce the frequency of manic episodes in patients with bipolar disorder or schizophrenia. Trials have also focused on mild to moderate agitation, raising questions about its efficacy in more severe cases. Moreover, it is also important to acknowledge the presence of mild side effects, including a slower onset compared to intramuscular injections, as well as somnolence, thirst, and hypotension, though no serious complications have been reported [<xref rid="r115" ref-type="bibr">115</xref>, <xref rid="r119" ref-type="bibr">119</xref>].</p><p>Despite the clinical approval of Dex for treating agitation, the underlying mechanism of its action remains unclear due to a lack of experimental research investigating the downstream targets through which Dex exerts its anti-agitation effects. In addition, one major challenge impeding relevant basic research is the absence of precise behavioral detection methods for assessing agitation in animal models. Traditional approaches relying on static parameters are insufficient for meaningful detection in animals displaying agitation or accurately identifying its subtypes.</p><p>To address these limitations, Cao <italic toggle="yes">et al</italic>. recently introduced a machine-learning-based method to overcome these challenges [<xref rid="r120" ref-type="bibr">120</xref>]. Using postoperative delirium (POD) schema, they proposed a comprehensive approach involving pose evaluation, behavior analysis, and action sequence evaluation to differentiate between the non-POD group and the POD group [<xref rid="r120" ref-type="bibr">120</xref>]. By employing a multi-scaled clustering analysis framework, these researchers successfully captured the hierarchical dynamics of delirium-like behaviors [<xref rid="r120" ref-type="bibr">120</xref>]. Notably, their findings showed that Dex reduced both the severity and incidence of POD in the animal model [<xref rid="r120" ref-type="bibr">120</xref>].</p><p>This innovative method not only enhances the accuracy of model construction but also enables the distinction of agitation subtypes. In the future, the researchers can explore the application of this approach to establish animal models of agitation and other neuropsychiatric diseases, facilitating investigations into the pathogenesis of these conditions and the therapeutic mechanisms of Dex. Such endeavors hold significant implications for understanding neuropsychiatric diseases and developing promising therapeutic interventions.</p></sec><sec id="sec3.7"><label>3.7</label><title>ASD</title><p>ASD is a neurodevelopmental disorder characterized by social difficulties, presenting with behavior commonly stereotyped for the inability to detect social cues [<xref rid="r121" ref-type="bibr">121</xref>]. In the United States, the prevalence of ASD has been steadily increasing, with approximately 2.3% of children and 2.2% of adults affected by the condition. The majority of individuals with ASD require assistance in daily living, placing a significant burden on both society and families.</p><p>In previous studies, Dex has demonstrated notable neuroprotective effects and exhibited positive therapeutic outcomes in cognitive and mood disorders [<xref rid="r13" ref-type="bibr">13</xref>]. These characteristics enable the researchers to turn their attention to investigating the potential therapeutic effects of Dex in ASD. Liang <italic toggle="yes">et al.</italic> conducted pioneering research and revealed the therapeutic effects of Dex on social disorders and stereotypical behavior in BTBR T<sup>+</sup> Itpr3<sup>tf</sup> /J (BTBR) mice, an established ASD model through three-chamber, self-grooming, marble burying, open field, and elevated plus maze [<xref rid="r122" ref-type="bibr">122</xref>]. Furthermore, this study uncovered the underlying mechanisms and identified that Dex exerted its effects by inhibiting the release of the inflammatory cytokine IL-6 and modulating abnormal excitation of glutaminergic neurons in the prelimbic cortex through &#945;2ARs activation [<xref rid="r122" ref-type="bibr">122</xref>]. These findings provide initial evidence supporting the beneficial effects of Dex on the core symptoms of ASD, thereby offering a theoretical foundation and potential therapeutic strategy for clinical interventions in ASD. Future studies could delve deeper into the involvement of other brain regions, encompassing both neurons and glial cells, to further elucidate the mechanisms underlying the therapeutic effects of Dex in ASD.</p><p>In clinical practice, Dex is primarily used as a sedative to facilitate necessary tests for individuals with ASD. Intranasal administration of Dex has demonstrated effective sedation and anxiety reduction in ASD patients [<xref rid="r123" ref-type="bibr">123</xref>-<xref rid="r125" ref-type="bibr">125</xref>]. However, intranasal administration may potentially cause psychological distress and increase the resistance to medical examinations among ASD patients. The introduction of BXCL501 presents a potential improvement in this regard. Future clinical investigations could explore the use of sublingual administration to achieve satisfactory sedation effects. Furthermore, given that there is currently a dearth of clinical studies examining the therapeutic potential of Dex in treating ASD, it is important for researchers to design appropriate clinical studies in this area to ascertain whether Dex indeed holds therapeutic efficacy for individuals with ASD.</p></sec></sec><sec sec-type="other3" id="sec4"><label>4</label><title>PHARMACOLOGICAL PROPERTIES AND SAFETY OF DEX</title><p>Dex undergoes primary elimination <italic toggle="yes">via</italic> hepatic biotransformation [<xref rid="r126" ref-type="bibr">126</xref>]. It exhibits a rapid distribution half-life of approximately 6 minutes, characterized by swift onset, with an elimination half-life of around 2 hours [<xref rid="r127" ref-type="bibr">127</xref>]. The relatively long half-life necessitates close monitoring of vital signs during medication to mitigate risks like respiratory depression. Despite its current utility, safety concerns persist with the use of Dex, primarily due to the absence of a rapidly acting reversal agent and is mostly administered intravenously in clinic, thereby significantly restricting its clinical application as a therapeutic intervention in neuropsychiatric disorders. The side effects of Dex mainly focus on its impact on hemodynamics, encompassing transient hypertension, hypotension, and bradycardia, induced by mechanisms such as vasoconstriction, sympathetic inhibition, and baroreflex-mediated parasympathetic activation [<xref rid="r5" ref-type="bibr">5</xref>, <xref rid="r6" ref-type="bibr">6</xref>]. These side effects in the treatment of neuropsychiatric disorders mirror those observed during the sedative administration of Dex [<xref rid="r115" ref-type="bibr">115</xref>]. While no severe adverse events have been reported, it remains essential to optimize the treatment regimen and diligently monitor patients' vital signs when administering Dex.</p><p>The management of neuropsychiatric disorders typically entails long treatment durations, often extending over several years or a lifetime. One limitation of current antipsychotics is the risk of developing resistance over time. Most research on Dex in neuropsychiatric disorders has focused on short-term use, but more studies are needed to assess the long-term viability and potential for resistance [<xref rid="r52" ref-type="bibr">52</xref>, <xref rid="r105" ref-type="bibr">105</xref>]. Besides, the treatment of neuropsychiatric disorders commonly necessitates a blend of multiple medications to achieve optimal therapeutic outcomes. Nevertheless, intricate treatment regimens may heighten the occurrence of side effects in patients. Currently, there is limited research on the combination of Dex with antipsychotics. Existing studies have primarily explored its anesthetic use, where Dex, combined with agents like sevoflurane or propofol, reduces the dosage of anesthetics and minimizes related side effects [<xref rid="r128" ref-type="bibr">128</xref>, <xref rid="r129" ref-type="bibr">129</xref>]. Some studies have indicated that the combination of Dex and ketamine yields superior results in alleviating preoperative anxiety in children compared to Dex alone, withoutadditional adverse effects [<xref rid="r130" ref-type="bibr">130</xref>, <xref rid="r131" ref-type="bibr">131</xref>]. Future research should focus on evaluating the therapeutic efficacy and safety of Dex when used alongside traditional antipsychotics, which could enhance treatment strategies and support the broader clinical use of Dex for neuropsychiatric disorders.</p></sec><sec sec-type="conclusions"><title>CONCLUSION AND FUTURE DIRECTIONS</title><p>In summary, Dex exhibits neuroprotective effects. In addition to its clinical use as a sedative and analgesic, Dex may hold promise as a potential option for the treatment of neuropsychiatric disorders. Despite the promising potential, much of the current research on Dex&#8217;s application in neuropsychiatric disorders is based on preclinical animal studies, and translating these findings into clinical practice remains a significant challenge. This may be attributed to several factors: (1) Animal models may not fully capture the intricacies of human neuropsychiatric disorders; (2) The underlying pathophysiology of many neuropsychiatric conditions is still poorly understood; (3) There are notable differences in higher brain network organization between rodents, even non-human primates, and humans, particularly in the types, localization, and density of specific neurons and receptor subtypes. These factors underscore the need for caution when extrapolating animal data to human clinical applications and highlight the importance of further research in this area. In addition, careful consideration should be given to factors such as dosage, frequency of administration, and treatment duration, as they can significantly influence outcomes. These considerations are crucial in study design and result interpretation to determine the optimal medication approach.</p><p>Certain questions regarding the mechanisms of Dex in these disorders remain unanswered. Specifically, the direct target of Dex in the treatment of neuropsychiatric diseases remains largely unknown. Further studies are required to elucidate how Dex targets specific brain regions and cell types in animal models of different neuropsychiatric disorders. A comprehensive understanding of these mechanisms will not only verify the Dex functions in these neuropsychiatric disorders but also facilitate the development of new drugs for these disorders.</p><p>Collectively, the reviewed evidence indicates that Dex could have therapeutic potential in various neuropsychiatric disorders. The identification of the neuroprotective properties of Dex, along with ongoing investigations into its mechanisms of action, offers promising insights into its possible applications in treating these conditions. These insights not only enhance our understanding of the broad application of Dex across diverse neuropsychiatric conditions but also refine our comprehension of the underlying pathophysiology. Importantly, they are anticipated to yield novel discoveries in the future. The FDA has approved the use of BXCL501 for agitation associated with schizophrenia and bipolar disorder in adult patients. Unlike traditional intravenous administration, sublingual administration offers distinct advantages, including enhanced patient cooperation and comfort, while also enabling the potential for long-term drug administration in individuals with neuropsychiatric conditions. The federal approval of BXCL501 may contributed to a broader clinical use of Dex as a therapeutic option for neuropsychiatric diseases.</p></sec></body><back><ack><title>ACKNOWLEDGEMENTS</title><p>Declared none.</p></ack><sec sec-type="competing-interests"><title>AUTHORS&#8217; CONTRIBUTIONS</title><p>The authors confirm their contribution to the paper as follows: XH: Conceptualization, drafted the manuscript, and prepared the illustrations. RL: Writed and revised manuscript, and funding acquisition. FL, XL, YL, QL and LY: Prepared figures and edited manuscript. XZ, AP and YT: Edited and revised manuscript. RJ: Conceptualization, supervision, edited and revised manuscript, and funding acquisition. All authors reviewed the results and approved the final version of the manuscript.</p></sec><glossary><title>LIST OF ABBREVIATIONS</title><def-list><def-item><term>AD</term><def><p>Alzheimer's Disease</p></def></def-item><def-item><term>ASD</term><def><p>Autism Spectrum Disorders</p></def></def-item><def-item><term>A&#946;</term><def><p>&#946;-amyloid</p></def></def-item><def-item><term>&#945;2A-ARs</term><def><p>&#945;2A Adrenergic Receptors</p></def></def-item><def-item><term>&#945;2ARs</term><def><p>&#945;2 Adrenergic Receptors</p></def></def-item><def-item><term>&#945;2B-ARs</term><def><p>&#945;2B Adrenergic Receptors</p></def></def-item><def-item><term>&#945;2C-ARs</term><def><p>&#945;2C Adrenergic Receptors</p></def></def-item><def-item><term>BTBR</term><def><p>BTBR T+ Itpr3tf/J</p></def></def-item><def-item><term>CRH<sup>PVH</sup></term><def><p>Corticotropin-releasing Hormone-producing Hypothalamic Paraventricular Neurons</p></def></def-item><def-item><term>DBS</term><def><p>Deep Brain Stimulation</p></def></def-item><def-item><term>Dex</term><def><p>Dexmedetomidine</p></def></def-item><def-item><term>ECoG</term><def><p>Electrocorticography</p></def></def-item><def-item><term>GAERS</term><def><p>Genetic Absence Epilepsy Rat from Strasbourg</p></def></def-item><def-item><term>MDD</term><def><p>Major Depressive Disorder</p></def></def-item><def-item><term>MEG</term><def><p>Magnetoencephalography</p></def></def-item><def-item><term>MER</term><def><p>Microelectrode Recordings</p></def></def-item><def-item><term>miRNAs</term><def><p>MicroRNAs</p></def></def-item><def-item><term>MPTP</term><def><p>Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</p></def></def-item><def-item><term>NE</term><def><p>Norepinephrine</p></def></def-item><def-item><term>P-tau</term><def><p>Hyperphosphorylated Tau</p></def></def-item><def-item><term>PD</term><def><p>Parkinson's Disease</p></def></def-item><def-item><term>POD</term><def><p>Postoperative Delirium</p></def></def-item><def-item><term>PTSD</term><def><p>Post-traumatic Stress Disorder</p></def></def-item><def-item><term>ROS</term><def><p>Reactive Oxygen Species</p></def></def-item><def-item><term>RT-PCR</term><def><p>Reverse Transcriptase Polymerase Chain Reaction</p></def></def-item><def-item><term>SN</term><def><p>Substantia Nigra</p></def></def-item><def-item><term>TREM2</term><def><p>Triggering Receptors Expressed on Myeloid Cells 2</p></def></def-item></def-list></glossary><sec sec-type="competing-interests"><title>CONSENT FOR PUBLICATION</title><p>Not applicable.</p></sec><sec sec-type="financial-disclosure"><title>FUNDING</title><p>This study was supported by the National Natural Science Foundation of China (No. 82401502), the Postdoctor Research Fund of West China Hospital of Sichuan University (2024HXBH100), the Sichuan Science and Technology Program (2023NSFSC1583), the Institutional Research Fund from Sichuan University (2023SCUH0046), the National Natural Science Foundation of China (No. 82271249), 1-3-5 Project for Disciplines of Excellence of West China Hospital of Sichuan University (ZYJC21034, and ZYYC23002).</p></sec><sec sec-type="COI-statement"><title>CONFLICT OF INTEREST</title><p>The authors declare no conflict of interest, financial or otherwise.</p></sec><ref-list><title>REFERENCES</title><ref id="r1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saleki</surname><given-names>K.</given-names></name><name name-style="western"><surname>Alijanizadeh</surname><given-names>P.</given-names></name><name name-style="western"><surname>Javanmehr</surname><given-names>N.</given-names></name><name name-style="western"><surname>Rezaei</surname><given-names>N.</given-names></name></person-group><article-title>The role of Toll-like receptors in neuropsychiatric disorders: Immunopathology, treatment, and management.</article-title><source>Med. Res. Rev.</source><year>2024</year><volume>44</volume><issue>3</issue><fpage>1267</fpage><lpage>1325</lpage><pub-id pub-id-type="doi">10.1002/med.22012</pub-id><pub-id pub-id-type="pmid">38226452</pub-id></element-citation></ref><ref id="r2"><label>2</label><element-citation publication-type="journal"><article-title>Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990-2019: A systematic analysis for the Global Burden of Disease Study 2019.</article-title><source>Lancet Psychiatry</source><year>2022</year><volume>9</volume><issue>2</issue><fpage>137</fpage><lpage>150</lpage><pub-id pub-id-type="doi">10.1016/S2215-0366(21)00395-3</pub-id><pub-id pub-id-type="pmid">35026139</pub-id><pub-id pub-id-type="pmcid">PMC8776563</pub-id></element-citation></ref><ref id="r3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gertler</surname><given-names>R.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>H.C.</given-names></name><name name-style="western"><surname>Mitchell</surname><given-names>D.H.</given-names></name><name name-style="western"><surname>Silvius</surname><given-names>E.N.</given-names></name></person-group><article-title>Dexmedetomidine: A novel sedative-analgesic agent.</article-title><source>Proc. Bayl. Univ. Med. Cent.</source><year>2001</year><volume>14</volume><issue>1</issue><fpage>13</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1080/08998280.2001.11927725</pub-id><pub-id pub-id-type="pmid">16369581</pub-id><pub-id pub-id-type="pmcid">PMC1291306</pub-id></element-citation></ref><ref id="r4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shehabi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ruettimann</surname><given-names>U.</given-names></name><name name-style="western"><surname>Adamson</surname><given-names>H.</given-names></name><name name-style="western"><surname>Innes</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ickeringill</surname><given-names>M.</given-names></name></person-group><article-title>Dexmedetomidine infusion for more than 24 hours in critically ill patients: Sedative and cardiovascular effects.</article-title><source>Intensive Care Med.</source><year>2004</year><volume>30</volume><issue>12</issue><fpage>2188</fpage><lpage>2196</lpage><pub-id pub-id-type="doi">10.1007/s00134-004-2417-z</pub-id><pub-id pub-id-type="pmid">15338124</pub-id></element-citation></ref><ref id="r5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bloor</surname><given-names>B.C.</given-names></name><name name-style="western"><surname>Ward</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Belleville</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Maze</surname><given-names>M.</given-names></name></person-group><article-title>Effects of intravenous dexmedetomidine in humans. II. Hemodynamic changes.</article-title><source>Anesthesiology</source><year>1992</year><volume>77</volume><issue>6</issue><fpage>1134</fpage><lpage>1142</lpage><pub-id pub-id-type="doi">10.1097/00000542-199212000-00014</pub-id><pub-id pub-id-type="pmid">1361311</pub-id></element-citation></ref><ref id="r6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ebert</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Hall</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Barney</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Uhrich</surname><given-names>T.D.</given-names></name><name name-style="western"><surname>Colinco</surname><given-names>M.D.</given-names></name></person-group><article-title>The effects of increasing plasma concentrations of dexmedetomidine in humans.</article-title><source>Anesthesiology</source><year>2000</year><volume>93</volume><issue>2</issue><fpage>382</fpage><lpage>394</lpage><pub-id pub-id-type="doi">10.1097/00000542-200008000-00016</pub-id><pub-id pub-id-type="pmid">10910487</pub-id></element-citation></ref><ref id="r7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Venn</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Grounds</surname><given-names>R.M.</given-names></name></person-group><article-title>Comparison between dexmedetomidine and propofol for sedation in the intensive care unit: Patient and clinician perceptions.</article-title><source>Br. J. Anaesth.</source><year>2001</year><volume>87</volume><issue>5</issue><fpage>684</fpage><lpage>690</lpage><pub-id pub-id-type="doi">10.1093/bja/87.5.684</pub-id><pub-id pub-id-type="pmid">11878517</pub-id></element-citation></ref><ref id="r8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jakob</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Ruokonen</surname><given-names>E.</given-names></name><name name-style="western"><surname>Grounds</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Sarapohja</surname><given-names>T.</given-names></name><name name-style="western"><surname>Garratt</surname><given-names>C.</given-names></name><name name-style="western"><surname>Pocock</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Bratty</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Takala</surname><given-names>J.</given-names></name></person-group><article-title>Dexmedetomidine vs. midazolam or propofol for sedation during prolonged mechanical ventilation: Two randomized controlled trials.</article-title><source>JAMA</source><year>2012</year><volume>307</volume><issue>11</issue><fpage>1151</fpage><lpage>1160</lpage><pub-id pub-id-type="doi">10.1001/jama.2012.304</pub-id><pub-id pub-id-type="pmid">22436955</pub-id></element-citation></ref><ref id="r9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Ferretti</surname><given-names>V.</given-names></name></person-group><article-title>G&#252;ntan, &#304;.; Moro, A.; Steinberg, E.A.; Ye, Z.; Zecharia, A.Y.; Yu, X.; Vyssotski, A.L.; Brickley, S.G.; Yustos, R.; Pillidge, Z.E.; Harding, E.C.; Wisden, W.; Franks, N.P. Neuronal ensembles sufficient for recovery sleep and the sedative actions of &#945;2 adrenergic agonists.</article-title><source>Nat. Neurosci.</source><year>2015</year><volume>18</volume><issue>4</issue><fpage>553</fpage><lpage>561</lpage><pub-id pub-id-type="doi">10.1038/nn.3957</pub-id><pub-id pub-id-type="pmid">25706476</pub-id><pub-id pub-id-type="pmcid">PMC4836567</pub-id></element-citation></ref><ref id="r10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Martin</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ramsay</surname><given-names>G.</given-names></name><name name-style="western"><surname>Mantz</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sum-Ping</surname><given-names>S.T.J.</given-names></name></person-group><article-title>The role of the &#945;2-adrenoceptor agonist dexmedetomidine in postsurgical sedation in the intensive care unit.</article-title><source>J. Intensive Care Med.</source><year>2003</year><volume>18</volume><issue>1</issue><fpage>29</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1177/0885066602239122</pub-id><pub-id pub-id-type="pmid">15189665</pub-id></element-citation></ref><ref id="r11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Turan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Duncan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Leung</surname><given-names>S.</given-names></name><name name-style="western"><surname>Karimi</surname><given-names>N.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mao</surname><given-names>G.</given-names></name><name name-style="western"><surname>Hargrave</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gillinov</surname><given-names>M.</given-names></name><name name-style="western"><surname>Trombetta</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ayad</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hassan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Feider</surname><given-names>A.</given-names></name><name name-style="western"><surname>Howard-Quijano</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ruetzler</surname><given-names>K.</given-names></name><name name-style="western"><surname>Sessler</surname><given-names>D.I.</given-names></name><name name-style="western"><surname>Bergese</surname><given-names>S.</given-names></name><name name-style="western"><surname>De Oliveira</surname><given-names>G.</given-names></name><name name-style="western"><surname>Honar</surname><given-names>H.</given-names></name><name name-style="western"><surname>Niazi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Elliott</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hamadnalla</surname><given-names>H.</given-names></name><name name-style="western"><surname>Chodavarapu</surname><given-names>P.</given-names></name><name name-style="western"><surname>Bajracharya</surname><given-names>G.</given-names></name><name name-style="western"><surname>Fitzgerald</surname><given-names>P.</given-names></name><name name-style="western"><surname>Cuko</surname><given-names>E.</given-names></name><name name-style="western"><surname>Akhtar</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Lokhande</surname><given-names>C.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>M.Z.</given-names></name><name name-style="western"><surname>Khoshknabi</surname><given-names>D.</given-names></name><name name-style="western"><surname>Riter</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Hutcherson</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yagar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Glosse</surname><given-names>L.</given-names></name><name name-style="western"><surname>Saha</surname><given-names>P.</given-names></name><name name-style="western"><surname>Raza</surname><given-names>S.</given-names></name></person-group><article-title>Dexmedetomidine for reduction of atrial fibrillation and delirium after cardiac surgery (DECADE): A randomised placebo-controlled trial.</article-title><source>Lancet</source><year>2020</year><volume>396</volume><issue>10245</issue><fpage>177</fpage><lpage>185</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)30631-0</pub-id><pub-id pub-id-type="pmid">32682483</pub-id></element-citation></ref><ref id="r12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hoffman</surname><given-names>W.E.</given-names></name><name name-style="western"><surname>Baughman</surname><given-names>V.L.</given-names></name><name name-style="western"><surname>Albrecht</surname><given-names>R.F.</given-names></name></person-group><article-title>Interaction of catecholamines and nitrous oxide ventilation during incomplete brain ischemia in rats.</article-title><source>Anesth. Analg.</source><year>1993</year><volume>77</volume><issue>5</issue><fpage>908</fpage><lpage>912</lpage><pub-id pub-id-type="doi">10.1213/00000539-199311000-00006</pub-id><pub-id pub-id-type="pmid">8105726</pub-id></element-citation></ref><ref id="r13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luo</surname><given-names>S.</given-names></name><name name-style="western"><surname>Li</surname><given-names>L.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>N.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>E.</given-names></name></person-group><article-title>Dexmedetomidine exerts an anti-inflammatory effect <italic toggle="yes">via</italic> &#945;2 adrenoceptors to alleviate cognitive dysfunction in 5xFAD mice.</article-title><source>Front. Aging Neurosci.</source><year>2022</year><volume>14</volume><fpage>978768</fpage><pub-id pub-id-type="doi">10.3389/fnagi.2022.978768</pub-id><pub-id pub-id-type="pmid">36204551</pub-id><pub-id pub-id-type="pmcid">PMC9531904</pub-id></element-citation></ref><ref id="r14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>C.</given-names></name><name name-style="western"><surname>Song</surname><given-names>D.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>T.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>O.</given-names></name></person-group><article-title>Dexmedetomidine protects SH-SY5Y cells against MPP+-induced declining of mitochondrial membrane potential and cell cycle deficits.</article-title><source>Eur. J. Neurosci.</source><year>2021</year><volume>54</volume><issue>1</issue><fpage>4141</fpage><lpage>4153</lpage><pub-id pub-id-type="doi">10.1111/ejn.15252</pub-id><pub-id pub-id-type="pmid">33905578</pub-id></element-citation></ref><ref id="r15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>C.</given-names></name></person-group><article-title>Dexmedetomidine provides protection against hippocampal neuron apoptosis and cognitive impairment in mice with Alzheimer&#8217;s disease by mediating the miR-129/YAP1/JAG1 axis.</article-title><source>Mol. Neurobiol.</source><year>2020</year><volume>57</volume><issue>12</issue><fpage>5044</fpage><lpage>5055</lpage><pub-id pub-id-type="doi">10.1007/s12035-020-02069-z</pub-id><pub-id pub-id-type="pmid">32839917</pub-id></element-citation></ref><ref id="r16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>P.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Han</surname><given-names>X.</given-names></name><name name-style="western"><surname>Xing</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>L.</given-names></name></person-group><article-title>Dexmedetomidine regulates 6-hydroxydopamine-induced microglial polarization.</article-title><source>Neurochem. Res.</source><year>2017</year><volume>42</volume><issue>5</issue><fpage>1524</fpage><lpage>1532</lpage><pub-id pub-id-type="doi">10.1007/s11064-017-2209-9</pub-id><pub-id pub-id-type="pmid">28247333</pub-id></element-citation></ref><ref id="r17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Dai</surname><given-names>Z.</given-names></name></person-group><article-title>The protective effects of dexmedetomidine on ischemic brain injury: A meta-analysis.</article-title><source>J. Clin. Anesth.</source><year>2017</year><volume>40</volume><fpage>25</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1016/j.jclinane.2017.04.003</pub-id><pub-id pub-id-type="pmid">28625441</pub-id></element-citation></ref><ref id="r18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bekker</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sturaitis</surname><given-names>M.K.</given-names></name></person-group><article-title>Dexmedetomidine for neurological surgery.</article-title><source>Oper. Neurosurg.</source><year>2005</year><volume>57</volume><issue>1</issue><supplement>Suppl.</supplement><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1227/01.NEU.0000163476.42034.A1</pub-id><pub-id pub-id-type="pmid">15987564</pub-id></element-citation></ref><ref id="r19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zeng</surname><given-names>W.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>X.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>K.</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhan</surname><given-names>L.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>W.</given-names></name></person-group><article-title>Intranasal dexmedetomidine for the treatment of pre-operative anxiety and insomnia: A prospective, randomized, controlled, and clinical trial.</article-title><source>Front. Psychiatry</source><year>2022</year><volume>13</volume><fpage>816893</fpage><pub-id pub-id-type="doi">10.3389/fpsyt.2022.816893</pub-id><pub-id pub-id-type="pmid">35711602</pub-id><pub-id pub-id-type="pmcid">PMC9197108</pub-id></element-citation></ref><ref id="r20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gong</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>S.</given-names></name></person-group><article-title>Parental presence and intranasal dexmedetomidine for the prevention of anxiety during anesthesia induction in children undergoing tonsillectomy and/or adenoidectomy surgery: A randomized controlled trial.</article-title><source>Front. Pharmacol.</source><year>2022</year><volume>13</volume><fpage>1015357</fpage><pub-id pub-id-type="doi">10.3389/fphar.2022.1015357</pub-id><pub-id pub-id-type="pmid">36601054</pub-id><pub-id pub-id-type="pmcid">PMC9806335</pub-id></element-citation></ref><ref id="r21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Virtanen</surname><given-names>R.</given-names></name><name name-style="western"><surname>Savola</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Saano</surname><given-names>V.</given-names></name><name name-style="western"><surname>Nyman</surname><given-names>L.</given-names></name></person-group><article-title>Characterization of the selectivity, specificity and potency of medetomidine as an &#945;2-adrenoceptor agonist.</article-title><source>Eur. J. Pharmacol.</source><year>1988</year><volume>150</volume><issue>1-2</issue><fpage>9</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1016/0014-2999(88)90744-3</pub-id><pub-id pub-id-type="pmid">2900154</pub-id></element-citation></ref><ref id="r22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hein</surname><given-names>L.</given-names></name></person-group><article-title>Adrenoceptors and signal transduction in neurons.</article-title><source>Cell Tissue Res.</source><year>2006</year><volume>326</volume><issue>2</issue><fpage>541</fpage><lpage>551</lpage><pub-id pub-id-type="doi">10.1007/s00441-006-0285-2</pub-id><pub-id pub-id-type="pmid">16896948</pub-id></element-citation></ref><ref id="r23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baron</surname><given-names>R.</given-names></name></person-group><article-title>Neuropathic pain: A clinical perspective.</article-title><source>Handb. Exp. Pharmacol.</source><year>2009</year><volume>194</volume><issue>194</issue><fpage>3</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1007/978-3-540-79090-7_1</pub-id><pub-id pub-id-type="pmid">19655103</pub-id></element-citation></ref><ref id="r24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scholz</surname><given-names>J.</given-names></name><name name-style="western"><surname>Finnerup</surname><given-names>N.B.</given-names></name><name name-style="western"><surname>Attal</surname><given-names>N.</given-names></name><name name-style="western"><surname>Aziz</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Baron</surname><given-names>R.</given-names></name><name name-style="western"><surname>Bennett</surname><given-names>M.I.</given-names></name><name name-style="western"><surname>Benoliel</surname><given-names>R.</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cruccu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Davis</surname><given-names>K.D.</given-names></name><name name-style="western"><surname>Evers</surname><given-names>S.</given-names></name><name name-style="western"><surname>First</surname><given-names>M.</given-names></name><name name-style="western"><surname>Giamberardino</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Hansson</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kaasa</surname><given-names>S.</given-names></name><name name-style="western"><surname>Korwisi</surname><given-names>B.</given-names></name><name name-style="western"><surname>Kosek</surname><given-names>E.</given-names></name><name name-style="western"><surname>Lavand&#8217;homme</surname><given-names>P.</given-names></name><name name-style="western"><surname>Nicholas</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nurmikko</surname><given-names>T.</given-names></name><name name-style="western"><surname>Perrot</surname><given-names>S.</given-names></name><name name-style="western"><surname>Raja</surname><given-names>S.N.</given-names></name><name name-style="western"><surname>Rice</surname><given-names>A.S.C.</given-names></name><name name-style="western"><surname>Rowbotham</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Schug</surname><given-names>S.</given-names></name><name name-style="western"><surname>Simpson</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>B.H.</given-names></name><name name-style="western"><surname>Svensson</surname><given-names>P.</given-names></name><name name-style="western"><surname>Vlaeyen</surname><given-names>J.W.S.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Barke</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rief</surname><given-names>W.</given-names></name><name name-style="western"><surname>Treede</surname><given-names>R.D.</given-names></name></person-group><article-title>The IASP classification of chronic pain for ICD-11: Chronic neuropathic pain.</article-title><source>Pain</source><year>2019</year><volume>160</volume><issue>1</issue><fpage>53</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.1097/j.pain.0000000000001365</pub-id><pub-id pub-id-type="pmid">30586071</pub-id><pub-id pub-id-type="pmcid">PMC6310153</pub-id></element-citation></ref><ref id="r25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Knaus</surname><given-names>A.</given-names></name></person-group><article-title>Muthig, V.; Schickinger, S.; Moura, E.; Beetz, N.; Gilsbach, R.; Hein, L. &#945;2-Adrenoceptor subtypes&#8212;Unexpected functions for receptors and ligands derived from gene-targeted mouse models.</article-title><source>Neurochem. Int.</source><year>2007</year><volume>51</volume><issue>5</issue><fpage>277</fpage><lpage>281</lpage><pub-id pub-id-type="doi">10.1016/j.neuint.2007.06.036</pub-id><pub-id pub-id-type="pmid">17664025</pub-id></element-citation></ref><ref id="r26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gambardella</surname><given-names>J.</given-names></name><name name-style="western"><surname>Fiordelisi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Avvisato</surname><given-names>R.</given-names></name><name name-style="western"><surname>Buonaiuto</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cerasuolo</surname><given-names>F.A.</given-names></name><name name-style="western"><surname>Sorriento</surname><given-names>D.</given-names></name><name name-style="western"><surname>Iaccarino</surname><given-names>G.</given-names></name></person-group><article-title>Adrenergic receptors in endothelial and vascular smooth muscle cells.</article-title><source>Curr. Opin. Physiol.</source><year>2023</year><volume>36</volume><fpage>100721</fpage><pub-id pub-id-type="doi">10.1016/j.cophys.2023.100721</pub-id></element-citation></ref><ref id="r27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Feldman</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bousquet</surname><given-names>P.</given-names></name></person-group><article-title>Role of cental &#945;2B-adrenergic receptors in blood pressure control and hypertension.</article-title><source>J. Hypertens.</source><year>2003</year><volume>21</volume><issue>5</issue><fpage>871</fpage><lpage>872</lpage><pub-id pub-id-type="doi">10.1097/00004872-200305000-00009</pub-id><pub-id pub-id-type="pmid">12714859</pub-id></element-citation></ref><ref id="r28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kanagy</surname><given-names>N.L.</given-names></name></person-group><article-title>&#945;2-Adrenergic receptor signalling in hypertension.</article-title><source>Clin. Sci.</source><year>2005</year><volume>109</volume><issue>5</issue><fpage>431</fpage><lpage>437</lpage><pub-id pub-id-type="doi">10.1042/CS20050101</pub-id><pub-id pub-id-type="pmid">16232127</pub-id></element-citation></ref><ref id="r29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alluri</surname><given-names>S.</given-names></name><name name-style="western"><surname>Eisenberg</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Grisanti</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Tanner</surname><given-names>M.</given-names></name><name name-style="western"><surname>Volkow</surname><given-names>N.D.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S.W.</given-names></name><name name-style="western"><surname>Kil</surname><given-names>K.E.</given-names></name></person-group><article-title>Preclinical evaluation of new C-11 labeled benzo-1,4-dioxane PET radiotracers for brain &#945;2C adrenergic receptors.</article-title><source>Eur. J. Med. Chem.</source><year>2022</year><volume>243</volume><fpage>114764</fpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2022.114764</pub-id><pub-id pub-id-type="pmid">36272201</pub-id><pub-id pub-id-type="pmcid">PMC12067315</pub-id></element-citation></ref><ref id="r30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Uys</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Shahid</surname><given-names>M.</given-names></name><name name-style="western"><surname>Harvey</surname><given-names>B.H.</given-names></name></person-group><article-title>Therapeutic potential of selectively targeting the &#945;2C-adrenoceptor in cognition, depression, and schizophrenia&#8212;new developments and future perspective.</article-title><source>Front. Psychiatry</source><year>2017</year><volume>8</volume><fpage>144</fpage><pub-id pub-id-type="doi">10.3389/fpsyt.2017.00144</pub-id><pub-id pub-id-type="pmid">28855875</pub-id><pub-id pub-id-type="pmcid">PMC5558054</pub-id></element-citation></ref><ref id="r31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sallinen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Holappa</surname><given-names>J.</given-names></name><name name-style="western"><surname>Koivisto</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kuokkanen</surname><given-names>K.</given-names></name><name name-style="western"><surname>Chapman</surname><given-names>H.</given-names></name><name name-style="western"><surname>Lehtim&#228;ki</surname><given-names>J.</given-names></name><name name-style="western"><surname>Piepponen</surname><given-names>P.</given-names></name><name name-style="western"><surname>Mijatovic</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tanila</surname><given-names>H.</given-names></name><name name-style="western"><surname>Virtanen</surname><given-names>R.</given-names></name><name name-style="western"><surname>Sirvi&#246;</surname><given-names>J.</given-names></name><name name-style="western"><surname>Haapalinna</surname><given-names>A.</given-names></name></person-group><article-title>Pharmacological characterisation of a structurally novel &#945;2C-adrenoceptor antagonist ORM-10921 and its effects in neuropsychiatric models.</article-title><source>Basic Clin. Pharmacol. Toxicol.</source><year>2013</year><volume>113</volume><issue>4</issue><fpage>239</fpage><lpage>249</lpage><pub-id pub-id-type="doi">10.1111/bcpt.12090</pub-id><pub-id pub-id-type="pmid">23718812</pub-id></element-citation></ref><ref id="r32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Uys</surname><given-names>M.</given-names></name><name name-style="western"><surname>Shahid</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sallinen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Dreyer</surname><given-names>W.</given-names></name><name name-style="western"><surname>Cockeran</surname><given-names>M.</given-names></name><name name-style="western"><surname>Harvey</surname><given-names>B.H.</given-names></name></person-group><article-title>The &#945;2C-adrenoceptor antagonist, ORM-10921, has antipsychotic-like effects in social isolation reared rats and bolsters the response to haloperidol.</article-title><source>Prog. Neuropsychopharmacol. Biol. Psychiatry</source><year>2016</year><volume>71</volume><fpage>108</fpage><lpage>116</lpage><pub-id pub-id-type="doi">10.1016/j.pnpbp.2016.07.002</pub-id><pub-id pub-id-type="pmid">27381554</pub-id></element-citation></ref><ref id="r33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sallinen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Haapalinna</surname><given-names>A.</given-names></name><name name-style="western"><surname>MacDonald</surname><given-names>E.</given-names></name><name name-style="western"><surname>Viitamaa</surname><given-names>T.</given-names></name><name name-style="western"><surname>L&#228;hdesm&#228;ki</surname><given-names>J.</given-names></name><name name-style="western"><surname>Rybnikova</surname><given-names>E.</given-names></name><name name-style="western"><surname>Pelto-Huikko</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kobilka</surname><given-names>B.K.</given-names></name><name name-style="western"><surname>Scheinin</surname><given-names>M.</given-names></name></person-group><article-title>Genetic alteration of the &#945;2-adrenoceptor subtype c in mice affects the development of behavioral despair and stress-induced increases in plasma corticosterone levels.</article-title><source>Mol. Psychiatry</source><year>1999</year><volume>4</volume><issue>5</issue><fpage>443</fpage><lpage>452</lpage><pub-id pub-id-type="doi">10.1038/sj.mp.4000543</pub-id><pub-id pub-id-type="pmid">10523817</pub-id></element-citation></ref><ref id="r34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schwartz</surname><given-names>T.L.</given-names></name><name name-style="western"><surname>Sachdeva</surname><given-names>S.</given-names></name><name name-style="western"><surname>Stahl</surname><given-names>S.M.</given-names></name></person-group><article-title>Glutamate neurocircuitry: Theoretical underpinnings in Schizophrenia.</article-title><source>Front. Pharmacol.</source><year>2012</year><volume>3</volume><fpage>195</fpage><pub-id pub-id-type="doi">10.3389/fphar.2012.00195</pub-id><pub-id pub-id-type="pmid">23189055</pub-id><pub-id pub-id-type="pmcid">PMC3505861</pub-id></element-citation></ref><ref id="r35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W.S.</given-names></name><name name-style="western"><surname>Ji</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Xiong</surname><given-names>Y.C.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.Q.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>H.</given-names></name></person-group><article-title>Involvement of spinal microglia and interleukin-18 in the anti-nociceptive effect of dexmedetomidine in rats subjected to CCI.</article-title><source>Neurosci. Lett.</source><year>2014</year><volume>560</volume><fpage>21</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1016/j.neulet.2013.12.012</pub-id><pub-id pub-id-type="pmid">24345418</pub-id></element-citation></ref><ref id="r36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reutter</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Richards</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Sumners</surname><given-names>C.</given-names></name></person-group><article-title>Regulation of alpha2A-adrenergic receptor expression by epinephrine in cultured astroglia from rat brain.</article-title><source>J. Neurochem.</source><year>1998</year><volume>70</volume><issue>1</issue><fpage>86</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1046/j.1471-4159.1998.70010086.x</pub-id><pub-id pub-id-type="pmid">9422350</pub-id></element-citation></ref><ref id="r37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mei</surname><given-names>B.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zuo</surname><given-names>Z.</given-names></name></person-group><article-title>Dexmedetomidine attenuates sepsis-associated inflammation and encephalopathy <italic toggle="yes">via</italic> central &#945;2A adrenoceptor.</article-title><source>Brain Behav. Immun.</source><year>2021</year><volume>91</volume><fpage>296</fpage><lpage>314</lpage><pub-id pub-id-type="doi">10.1016/j.bbi.2020.10.008</pub-id><pub-id pub-id-type="pmid">33039659</pub-id><pub-id pub-id-type="pmcid">PMC7749843</pub-id></element-citation></ref><ref id="r38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gyoneva</surname><given-names>S.</given-names></name><name name-style="western"><surname>Traynelis</surname><given-names>S.F.</given-names></name></person-group><article-title>Norepinephrine modulates the motility of resting and activated microglia <italic toggle="yes">via</italic> different adrenergic receptors.</article-title><source>J. Biol. Chem.</source><year>2013</year><volume>288</volume><issue>21</issue><fpage>15291</fpage><lpage>15302</lpage><pub-id pub-id-type="doi">10.1074/jbc.M113.458901</pub-id><pub-id pub-id-type="pmid">23548902</pub-id><pub-id pub-id-type="pmcid">PMC3663549</pub-id></element-citation></ref><ref id="r39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mei</surname><given-names>B.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Weng</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>P.</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name></person-group><article-title>Activating astrocytic &#945;2A adrenoceptors in hippocampus reduces glutamate toxicity to attenuate sepsis-associated encephalopathy in mice.</article-title><source>Brain Behav. Immun.</source><year>2024</year><volume>117</volume><fpage>376</fpage><lpage>398</lpage><pub-id pub-id-type="doi">10.1016/j.bbi.2024.02.005</pub-id><pub-id pub-id-type="pmid">38320682</pub-id></element-citation></ref><ref id="r40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>An</surname><given-names>P.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>X.C.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>You</surname><given-names>Y.Q.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Gong</surname><given-names>H.S.</given-names></name></person-group><article-title>Dexmedetomidine alleviates intracerebral hemorrhage-induced anxiety-like behaviors in mice through the inhibition of TRPV4 opening.</article-title><source>Front. Pharmacol.</source><year>2022</year><volume>13</volume><fpage>852401</fpage><pub-id pub-id-type="doi">10.3389/fphar.2022.852401</pub-id><pub-id pub-id-type="pmid">35431940</pub-id><pub-id pub-id-type="pmcid">PMC9012538</pub-id></element-citation></ref><ref id="r41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Du</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Niu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>G.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>Y.W.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>W.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bresnahan</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Maze</surname><given-names>M.</given-names></name><name name-style="western"><surname>Beattie</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>J.Z.</given-names></name></person-group><article-title>Dexmedetomidine modulates neuroinflammation and improves outcome <italic toggle="yes">via</italic> alpha2-adrenergic receptor signaling after rat spinal cord injury.</article-title><source>Br. J. Anaesth.</source><year>2019</year><volume>123</volume><issue>6</issue><fpage>827</fpage><lpage>838</lpage><pub-id pub-id-type="doi">10.1016/j.bja.2019.08.026</pub-id><pub-id pub-id-type="pmid">31623841</pub-id><pub-id pub-id-type="pmcid">PMC6883489</pub-id></element-citation></ref><ref id="r42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name></person-group><article-title>Dexmedetomidine blocks thermal hyperalgesia and spinal glial activation in rat model of monoarthritis.</article-title><source>Acta Pharmacol. Sin.</source><year>2010</year><volume>31</volume><issue>5</issue><fpage>523</fpage><lpage>530</lpage><pub-id pub-id-type="doi">10.1038/aps.2010.32</pub-id><pub-id pub-id-type="pmid">20364156</pub-id><pub-id pub-id-type="pmcid">PMC4002747</pub-id></element-citation></ref><ref id="r43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Gangoso</surname><given-names>E.</given-names></name><name name-style="western"><surname>Yi</surname><given-names>C.</given-names></name><name name-style="western"><surname>Jeanson</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kandelman</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mantz</surname><given-names>J.</given-names></name><name name-style="western"><surname>Giaume</surname><given-names>C.</given-names></name></person-group><article-title>General anesthetics have differential inhibitory effects on gap junction channels and hemichannels in astrocytes and neurons.</article-title><source>Glia</source><year>2016</year><volume>64</volume><issue>4</issue><fpage>524</fpage><lpage>536</lpage><pub-id pub-id-type="doi">10.1002/glia.22946</pub-id><pub-id pub-id-type="pmid">26666873</pub-id></element-citation></ref><ref id="r44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scheltens</surname><given-names>P.</given-names></name><name name-style="western"><surname>Blennow</surname><given-names>K.</given-names></name><name name-style="western"><surname>Breteler</surname><given-names>M.M.B.</given-names></name><name name-style="western"><surname>de Strooper</surname><given-names>B.</given-names></name><name name-style="western"><surname>Frisoni</surname><given-names>G.B.</given-names></name><name name-style="western"><surname>Salloway</surname><given-names>S.</given-names></name><name name-style="western"><surname>Van der Flier</surname><given-names>W.M.</given-names></name></person-group><article-title>Alzheimer&#8217;s disease.</article-title><source>Lancet</source><year>2016</year><volume>388</volume><issue>10043</issue><fpage>505</fpage><lpage>517</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(15)01124-1</pub-id><pub-id pub-id-type="pmid">26921134</pub-id></element-citation></ref><ref id="r45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kinney</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Bemiller</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Murtishaw</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Leisgang</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Salazar</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Lamb</surname><given-names>B.T.</given-names></name></person-group><article-title>Inflammation as a central mechanism in Alzheimer&#8217;s disease.</article-title><source>Alzheimers Dement.</source><year>2018</year><volume>4</volume><issue>1</issue><fpage>575</fpage><lpage>590</lpage><pub-id pub-id-type="doi">10.1016/j.trci.2018.06.014</pub-id><pub-id pub-id-type="pmid">30406177</pub-id><pub-id pub-id-type="pmcid">PMC6214864</pub-id></element-citation></ref><ref id="r46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heneka</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Carson</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Khoury</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Landreth</surname><given-names>G.E.</given-names></name><name name-style="western"><surname>Brosseron</surname><given-names>F.</given-names></name><name name-style="western"><surname>Feinstein</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Jacobs</surname><given-names>A.H.</given-names></name><name name-style="western"><surname>Wyss-Coray</surname><given-names>T.</given-names></name><name name-style="western"><surname>Vitorica</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ransohoff</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Herrup</surname><given-names>K.</given-names></name><name name-style="western"><surname>Frautschy</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Finsen</surname><given-names>B.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>G.C.</given-names></name><name name-style="western"><surname>Verkhratsky</surname><given-names>A.</given-names></name><name name-style="western"><surname>Yamanaka</surname><given-names>K.</given-names></name><name name-style="western"><surname>Koistinaho</surname><given-names>J.</given-names></name><name name-style="western"><surname>Latz</surname><given-names>E.</given-names></name><name name-style="western"><surname>Halle</surname><given-names>A.</given-names></name><name name-style="western"><surname>Petzold</surname><given-names>G.C.</given-names></name><name name-style="western"><surname>Town</surname><given-names>T.</given-names></name><name name-style="western"><surname>Morgan</surname><given-names>D.</given-names></name><name name-style="western"><surname>Shinohara</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Perry</surname><given-names>V.H.</given-names></name><name name-style="western"><surname>Holmes</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bazan</surname><given-names>N.G.</given-names></name><name name-style="western"><surname>Brooks</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Hunot</surname><given-names>S.</given-names></name><name name-style="western"><surname>Joseph</surname><given-names>B.</given-names></name><name name-style="western"><surname>Deigendesch</surname><given-names>N.</given-names></name><name name-style="western"><surname>Garaschuk</surname><given-names>O.</given-names></name><name name-style="western"><surname>Boddeke</surname><given-names>E.</given-names></name><name name-style="western"><surname>Dinarello</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Breitner</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Cole</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>Golenbock</surname><given-names>D.T.</given-names></name><name name-style="western"><surname>Kummer</surname><given-names>M.P.</given-names></name></person-group><article-title>Neuroinflammation in Alzheimer&#8217;s disease.</article-title><source>Lancet Neurol.</source><year>2015</year><volume>14</volume><issue>4</issue><fpage>388</fpage><lpage>405</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(15)70016-5</pub-id><pub-id pub-id-type="pmid">25792098</pub-id><pub-id pub-id-type="pmcid">PMC5909703</pub-id></element-citation></ref><ref id="r47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Santa-Maria</surname><given-names>I.</given-names></name><name name-style="western"><surname>Varghese</surname><given-names>M.</given-names></name></person-group><article-title>Ksi&#553;&#380;ak-Reding, H.; Dzhun, A.; Wang, J.; Pasinetti, G.M. Paired helical filaments from Alzheimer disease brain induce intracellular accumulation of Tau protein in aggresomes.</article-title><source>J. Biol. Chem.</source><year>2012</year><volume>287</volume><issue>24</issue><fpage>20522</fpage><lpage>20533</lpage><pub-id pub-id-type="doi">10.1074/jbc.M111.323279</pub-id><pub-id pub-id-type="pmid">22496370</pub-id><pub-id pub-id-type="pmcid">PMC3370237</pub-id></element-citation></ref><ref id="r48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Veerhuis</surname><given-names>R.</given-names></name><name name-style="western"><surname>Van Breemen</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Hoozemans</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Morbin</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ouladhadj</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tagliavini</surname><given-names>F.</given-names></name><name name-style="western"><surname>Eikelenboom</surname><given-names>P.</given-names></name></person-group><article-title>Amyloid &#946; plaque-associated proteins C1q and SAP enhance the A&#946;1&#8211;42 peptide-induced cytokine secretion by adult human microglia in vitro.</article-title><source>Acta Neuropathol.</source><year>2003</year><volume>105</volume><issue>2</issue><fpage>135</fpage><lpage>144</lpage><pub-id pub-id-type="doi">10.1007/s00401-002-0624-7</pub-id><pub-id pub-id-type="pmid">12536224</pub-id></element-citation></ref><ref id="r49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garwood</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Pooler</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Atherton</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hanger</surname><given-names>D.P.</given-names></name><name name-style="western"><surname>Noble</surname><given-names>W.</given-names></name></person-group><article-title>Astrocytes are important mediators of A&#946;-induced neurotoxicity and tau phosphorylation in primary culture.</article-title><source>Cell Death Dis.</source><year>2011</year><volume>2</volume><issue>6</issue><fpage>e167</fpage><pub-id pub-id-type="doi">10.1038/cddis.2011.50</pub-id><pub-id pub-id-type="pmid">21633390</pub-id><pub-id pub-id-type="pmcid">PMC3168992</pub-id></element-citation></ref><ref id="r50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kitazawa</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yamasaki</surname><given-names>T.R.</given-names></name><name name-style="western"><surname>Laferla</surname><given-names>F.M.</given-names></name></person-group><article-title>Microglia as a potential bridge between the amyloid &#946;-peptide and tau.</article-title><source>Ann. N. Y. Acad. Sci.</source><year>2004</year><volume>1035</volume><issue>1</issue><fpage>85</fpage><lpage>103</lpage><pub-id pub-id-type="doi">10.1196/annals.1332.006</pub-id><pub-id pub-id-type="pmid">15681802</pub-id></element-citation></ref><ref id="r51"><label>51</label><element-citation publication-type="journal"><article-title>2023 Alzheimer&#8217;s disease facts and figures.</article-title><source>Alzheimers Dement.</source><year>2023</year><volume>19</volume><issue>4</issue><fpage>1598</fpage><lpage>1695</lpage><pub-id pub-id-type="doi">10.1002/alz.13016</pub-id><pub-id pub-id-type="pmid">36918389</pub-id></element-citation></ref><ref id="r52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lian</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>W.</given-names></name><name name-style="western"><surname>Xue</surname><given-names>F.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>G.</given-names></name></person-group><article-title>Dexmedetomidine mitigates neuroinflammation in an Alzheimer&#8217;s disease mouse model <italic toggle="yes">via</italic> the miR-204-3p/FBXL7 signaling axis.</article-title><source>Brain Res.</source><year>2024</year><volume>1822</volume><fpage>148612</fpage><pub-id pub-id-type="doi">10.1016/j.brainres.2023.148612</pub-id><pub-id pub-id-type="pmid">37778649</pub-id></element-citation></ref><ref id="r53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tan</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Y.</given-names></name></person-group><article-title>Dexmedetomidine promoted HSPB8 expression <italic toggle="yes">via</italic> inhibiting the lncRNA SNHG14/UPF1 axis to inhibit apoptosis of nerve cells in AD.</article-title><source>Neurotox. Res.</source><year>2023</year><volume>41</volume><issue>5</issue><fpage>471</fpage><lpage>480</lpage><pub-id pub-id-type="doi">10.1007/s12640-023-00653-4</pub-id><pub-id pub-id-type="pmid">37656385</pub-id></element-citation></ref><ref id="r54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arslan</surname><given-names>M.</given-names></name><name name-style="western"><surname>K&#252;&#231;&#252;k</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kiran</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>K&#246;ksal</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Kurtipek</surname><given-names>O.</given-names></name><name name-style="western"><surname>Kavut&#231;u</surname><given-names>M.</given-names></name></person-group><article-title>Evaluation of the effects of recurrent dexmedetomidine on cognitive functions and brain tissue in streptozotocin-induced rats with Alzheimer&#8217;s disease.</article-title><source>Gazi Med J.</source><year>2022</year><volume>33</volume><issue>1</issue><fpage>5</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.12996/gmj.2022.02</pub-id></element-citation></ref><ref id="r55"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>N.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name></person-group><article-title>Up-regulation of miRNA-151-3p enhanced the neuroprotective effect of dexmedetomidine against &#946;-amyloid by targeting DAPK-1 and TP53.</article-title><source>Exp. Mol. Pathol.</source><year>2021</year><volume>118</volume><fpage>104587</fpage><pub-id pub-id-type="doi">10.1016/j.yexmp.2020.104587</pub-id><pub-id pub-id-type="pmid">33275947</pub-id></element-citation></ref><ref id="r56"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>P.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>He</surname><given-names>G.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>X.</given-names></name></person-group><article-title>Modulation of microglial phenotypes by dexmedetomidine through TREM2 reduces neuroinflammation in heatstroke.</article-title><source>Sci. Rep.</source><year>2021</year><volume>11</volume><issue>1</issue><fpage>13345</fpage><pub-id pub-id-type="doi">10.1038/s41598-021-92906-5</pub-id><pub-id pub-id-type="pmid">34172807</pub-id><pub-id pub-id-type="pmcid">PMC8233427</pub-id></element-citation></ref><ref id="r57"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guerreiro</surname><given-names>R.</given-names></name><name name-style="western"><surname>Wojtas</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bras</surname><given-names>J.</given-names></name><name name-style="western"><surname>Carrasquillo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rogaeva</surname><given-names>E.</given-names></name><name name-style="western"><surname>Majounie</surname><given-names>E.</given-names></name><name name-style="western"><surname>Cruchaga</surname><given-names>C.</given-names></name><name name-style="western"><surname>Sassi</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kauwe</surname><given-names>J.S.K.</given-names></name><name name-style="western"><surname>Younkin</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hazrati</surname><given-names>L.</given-names></name><name name-style="western"><surname>Collinge</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pocock</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lashley</surname><given-names>T.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lambert</surname><given-names>J-C.</given-names></name><name name-style="western"><surname>Amouyel</surname><given-names>P.</given-names></name><name name-style="western"><surname>Goate</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rademakers</surname><given-names>R.</given-names></name><name name-style="western"><surname>Morgan</surname><given-names>K.</given-names></name><name name-style="western"><surname>Powell</surname><given-names>J.</given-names></name><name name-style="western"><surname>St George-Hyslop</surname><given-names>P.</given-names></name><name name-style="western"><surname>Singleton</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hardy</surname><given-names>J.</given-names></name></person-group><article-title>TREM2 variants in Alzheimer&#8217;s disease.</article-title><source>N. Engl. J. Med.</source><year>2013</year><volume>368</volume><issue>2</issue><fpage>117</fpage><lpage>127</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1211851</pub-id><pub-id pub-id-type="pmid">23150934</pub-id><pub-id pub-id-type="pmcid">PMC3631573</pub-id></element-citation></ref><ref id="r58"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arranz</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>De Strooper</surname><given-names>B.</given-names></name></person-group><article-title>The role of astroglia in Alzheimer&#8217;s disease: Pathophysiology and clinical implications.</article-title><source>Lancet Neurol.</source><year>2019</year><volume>18</volume><issue>4</issue><fpage>406</fpage><lpage>414</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(18)30490-3</pub-id><pub-id pub-id-type="pmid">30795987</pub-id></element-citation></ref><ref id="r59"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Madadi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Schwarzenbach</surname><given-names>H.</given-names></name><name name-style="western"><surname>Saidijam</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mahjub</surname><given-names>R.</given-names></name><name name-style="western"><surname>Soleimani</surname><given-names>M.</given-names></name></person-group><article-title>Potential microRNA-related targets in clearance pathways of amyloid-&#946; Novel therapeutic approach for the treatment of Alzheimer&#8217;s disease.</article-title><source>Cell Biosci.</source><year>2019</year><volume>9</volume><issue>1</issue><fpage>91</fpage><pub-id pub-id-type="doi">10.1186/s13578-019-0354-3</pub-id><pub-id pub-id-type="pmid">31749959</pub-id><pub-id pub-id-type="pmcid">PMC6852943</pub-id></element-citation></ref><ref id="r60"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Shao</surname><given-names>W.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>B.</given-names></name></person-group><article-title>MicroRNA-214-5p involves in the protection effect of Dexmedetomidine against neurological injury in Alzheimer&#8217;s disease <italic toggle="yes">via</italic> targeting the suppressor of zest 12.</article-title><source>Brain Res. Bull.</source><year>2022</year><volume>178</volume><fpage>164</fpage><lpage>172</lpage><pub-id pub-id-type="doi">10.1016/j.brainresbull.2021.10.016</pub-id><pub-id pub-id-type="pmid">34715270</pub-id></element-citation></ref><ref id="r61"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Whittington</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Vir&#225;g</surname><given-names>L.</given-names></name><name name-style="western"><surname>Gratuze</surname><given-names>M.</given-names></name><name name-style="western"><surname>Petry</surname><given-names>F.R.</given-names></name><name name-style="western"><surname>No&#235;l</surname><given-names>A.</given-names></name><name name-style="western"><surname>Poitras</surname><given-names>I.</given-names></name><name name-style="western"><surname>Truchetti</surname><given-names>G.</given-names></name><name name-style="western"><surname>Marcouiller</surname><given-names>F.</given-names></name><name name-style="western"><surname>Papon</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>El Khoury</surname><given-names>N.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>K.</given-names></name><name name-style="western"><surname>Bretteville</surname><given-names>A.</given-names></name><name name-style="western"><surname>Morin</surname><given-names>F.</given-names></name><name name-style="western"><surname>Planel</surname><given-names>E.</given-names></name></person-group><article-title>Dexmedetomidine increases tau phosphorylation under normothermic conditions <italic toggle="yes">in vivo</italic> and in vitro.</article-title><source>Neurobiol. Aging</source><year>2015</year><volume>36</volume><issue>8</issue><fpage>2414</fpage><lpage>2428</lpage><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2015.05.002</pub-id><pub-id pub-id-type="pmid">26058840</pub-id><pub-id pub-id-type="pmcid">PMC4465078</pub-id></element-citation></ref><ref id="r62"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>D.</given-names></name><name name-style="western"><surname>Clark</surname><given-names>E.D.</given-names></name><name name-style="western"><surname>Antonsdottir</surname><given-names>I.M.</given-names></name><name name-style="western"><surname>Porsteinsson</surname><given-names>A.P.A.</given-names></name></person-group><article-title>2023 update on the advancements in the treatment of agitation in Alzheimer&#8217;s disease.</article-title><source>Expert Opin. Pharmacother.</source><year>2023</year><volume>24</volume><issue>6</issue><fpage>691</fpage><lpage>703</lpage><pub-id pub-id-type="doi">10.1080/14656566.2023.2195539</pub-id><pub-id pub-id-type="pmid">36958727</pub-id></element-citation></ref><ref id="r63"><label>63</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bloem</surname><given-names>B.R.</given-names></name><name name-style="western"><surname>Okun</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Klein</surname><given-names>C.</given-names></name></person-group><article-title>Parkinson&#8217;s disease.</article-title><source>Lancet</source><year>2021</year><volume>397</volume><issue>10291</issue><fpage>2284</fpage><lpage>2303</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(21)00218-X</pub-id><pub-id pub-id-type="pmid">33848468</pub-id></element-citation></ref><ref id="r64"><label>64</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>L.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>T.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>H.</given-names></name></person-group><article-title>Dexmedetomidine attenuates motor deficits <italic toggle="yes">via</italic> restoring the function of neurons in the nigrostriatal circuit in Parkinson&#8217;s disease model mice.</article-title><source>Eur. J. Pharmacol.</source><year>2022</year><volume>920</volume><fpage>174806</fpage><pub-id pub-id-type="doi">10.1016/j.ejphar.2022.174806</pub-id><pub-id pub-id-type="pmid">35150656</pub-id></element-citation></ref><ref id="r65"><label>65</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>X.</given-names></name></person-group><article-title>Dexmedetomidine protects against degeneration of dopaminergic neurons and improves motor activity in Parkinson&#8217;s disease mice model.</article-title><source>Saudi J. Biol. Sci.</source><year>2021</year><volume>28</volume><issue>6</issue><fpage>3198</fpage><lpage>3203</lpage><pub-id pub-id-type="doi">10.1016/j.sjbs.2021.04.013</pub-id><pub-id pub-id-type="pmid">34121856</pub-id><pub-id pub-id-type="pmcid">PMC8176059</pub-id></element-citation></ref><ref id="r66"><label>66</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>S.P.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.X.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>H.F.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>C.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Gui</surname><given-names>J.B.</given-names></name></person-group><article-title>Dexmedetomidine increases acetylation level of histone through ERK1/2 pathway in dopamine neuron.</article-title><source>Hum. Exp. Toxicol.</source><year>2017</year><volume>36</volume><issue>5</issue><fpage>474</fpage><lpage>482</lpage><pub-id pub-id-type="doi">10.1177/0960327116652458</pub-id><pub-id pub-id-type="pmid">27334975</pub-id></element-citation></ref><ref id="r67"><label>67</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Whittington</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Vir&#225;g</surname><given-names>L.</given-names></name></person-group><article-title>Dexmedetomidine-induced decreases in accumbal dopamine in the rat are partly mediated <italic toggle="yes">via</italic> the locus coeruleus.</article-title><source>Anesth. Analg.</source><year>2006</year><volume>102</volume><issue>2</issue><fpage>448</fpage><lpage>455</lpage><pub-id pub-id-type="doi">10.1213/01.ane.0000195234.07413.5a</pub-id><pub-id pub-id-type="pmid">16428541</pub-id></element-citation></ref><ref id="r68"><label>68</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Suzuki</surname><given-names>T.</given-names></name><name name-style="western"><surname>Sasajima</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ueta</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ishida</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hashimoto</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tachi</surname><given-names>N.</given-names></name></person-group><article-title>Epiretinal membrane surgery for a patient with dyskinesia related to Parkinson&#8217;s disease using intravenous dexmedetomidine administration.</article-title><source>Case Rep. Ophthalmol.</source><year>2022</year><volume>13</volume><issue>3</issue><fpage>967</fpage><lpage>971</lpage><pub-id pub-id-type="doi">10.1159/000527157</pub-id><pub-id pub-id-type="pmid">36466054</pub-id><pub-id pub-id-type="pmcid">PMC9710442</pub-id></element-citation></ref><ref id="r69"><label>69</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>H.</given-names></name></person-group><article-title>Intraoperative relief of resting tremor by dexmedetomidine in a patient with Parkinson&#8217;s disease.</article-title><source>Asian J. Surg.</source><year>2024</year><volume>47</volume><issue>4</issue><fpage>1951</fpage><lpage>1952</lpage><pub-id pub-id-type="doi">10.1016/j.asjsur.2023.12.162</pub-id><pub-id pub-id-type="pmid">38212224</pub-id></element-citation></ref><ref id="r70"><label>70</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nakajima</surname><given-names>T.</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Miyaue</surname><given-names>N.</given-names></name></person-group><article-title>Successful management of Parkinson&#8217;s disease dyskinesia during local anesthesia with dexmedetomidine.</article-title><source>Cureus</source><year>2021</year><volume>13</volume><issue>3</issue><fpage>e13739</fpage><pub-id pub-id-type="doi">10.7759/cureus.13739</pub-id><pub-id pub-id-type="pmid">33842117</pub-id><pub-id pub-id-type="pmcid">PMC8020600</pub-id></element-citation></ref><ref id="r71"><label>71</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>P.S.</given-names></name><name name-style="western"><surname>Crammond</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Richardson</surname><given-names>R.M.</given-names></name></person-group><article-title>Deep brain stimulation of the subthalamic nucleus and globus pallidus for Parkinson&#8217;s disease.</article-title><source>Prog. Neurol. Surg.</source><year>2018</year><volume>33</volume><fpage>207</fpage><lpage>221</lpage><pub-id pub-id-type="doi">10.1159/000481105</pub-id><pub-id pub-id-type="pmid">29332085</pub-id></element-citation></ref><ref id="r72"><label>72</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krack</surname><given-names>P.</given-names></name><name name-style="western"><surname>Batir</surname><given-names>A.</given-names></name><name name-style="western"><surname>Van Blercom</surname><given-names>N.</given-names></name><name name-style="western"><surname>Chabardes</surname><given-names>S.</given-names></name><name name-style="western"><surname>Fraix</surname><given-names>V.</given-names></name><name name-style="western"><surname>Ardouin</surname><given-names>C.</given-names></name><name name-style="western"><surname>Koudsie</surname><given-names>A.</given-names></name><name name-style="western"><surname>Limousin</surname><given-names>P.D.</given-names></name><name name-style="western"><surname>Benazzouz</surname><given-names>A.</given-names></name><name name-style="western"><surname>LeBas</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Benabid</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Pollak</surname><given-names>P.</given-names></name></person-group><article-title>Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson&#8217;s disease.</article-title><source>N. Engl. J. Med.</source><year>2003</year><volume>349</volume><issue>20</issue><fpage>1925</fpage><lpage>1934</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa035275</pub-id><pub-id pub-id-type="pmid">14614167</pub-id></element-citation></ref><ref id="r73"><label>73</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bos</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Sanchez</surname><given-names>A.M.A.</given-names></name><name name-style="western"><surname>Bancone</surname><given-names>R.</given-names></name><name name-style="western"><surname>Temel</surname><given-names>Y.</given-names></name><name name-style="western"><surname>de Greef</surname><given-names>B.T.A.</given-names></name><name name-style="western"><surname>Absalom</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Gommer</surname><given-names>E.D.</given-names></name><name name-style="western"><surname>van Kranen-Mastenbroek</surname><given-names>V.H.J.M.</given-names></name><name name-style="western"><surname>Buhre</surname><given-names>W.F.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Janssen</surname><given-names>M.L.F.</given-names></name></person-group><article-title>Influence of anesthesia and clinical variables on the firing rate, coefficient of variation and multi-unit activity of the subthalamic nucleus in patients with Parkinson&#8217;s disease.</article-title><source>J. Clin. Med.</source><year>2020</year><volume>9</volume><issue>4</issue><fpage>1229</fpage><pub-id pub-id-type="doi">10.3390/jcm9041229</pub-id><pub-id pub-id-type="pmid">32344572</pub-id><pub-id pub-id-type="pmcid">PMC7230272</pub-id></element-citation></ref><ref id="r74"><label>74</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mulroy</surname><given-names>E.</given-names></name><name name-style="western"><surname>Robertson</surname><given-names>N.</given-names></name><name name-style="western"><surname>Macdonald</surname><given-names>L.</given-names></name><name name-style="western"><surname>Bok</surname><given-names>A.</given-names></name><name name-style="western"><surname>Simpson</surname><given-names>M.</given-names></name></person-group><article-title>Patients&#8217; perioperative experience of awake deep-brain stimulation for Parkinson disease.</article-title><source>World Neurosurg.</source><year>2017</year><volume>105</volume><fpage>526</fpage><lpage>528</lpage><pub-id pub-id-type="doi">10.1016/j.wneu.2017.05.132</pub-id><pub-id pub-id-type="pmid">28606582</pub-id></element-citation></ref><ref id="r75"><label>75</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Martinez-Simon</surname><given-names>A.</given-names></name><name name-style="western"><surname>Valencia</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cacho-Asenjo</surname><given-names>E.</given-names></name><name name-style="western"><surname>Honorato-Cia</surname><given-names>C.</given-names></name><name name-style="western"><surname>Nu&#241;ez-Cordoba</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Manzanilla</surname><given-names>O.</given-names></name><name name-style="western"><surname>Aldaz</surname><given-names>A.</given-names></name><name name-style="western"><surname>Panadero</surname><given-names>A.</given-names></name><name name-style="western"><surname>Guridi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Alegre</surname><given-names>M.</given-names></name></person-group><article-title>Effects of dexmedetomidine on subthalamic local field potentials in Parkinson&#8217;s disease.</article-title><source>Br. J. Anaesth.</source><year>2021</year><volume>127</volume><issue>2</issue><fpage>245</fpage><lpage>253</lpage><pub-id pub-id-type="doi">10.1016/j.bja.2021.01.036</pub-id><pub-id pub-id-type="pmid">33896591</pub-id><pub-id pub-id-type="pmcid">PMC8362272</pub-id></element-citation></ref><ref id="r76"><label>76</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sassi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zekaj</surname><given-names>E.</given-names></name><name name-style="western"><surname>Grotta</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pollini</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pellanda</surname><given-names>A.</given-names></name><name name-style="western"><surname>Borroni</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pacchetti</surname><given-names>C.</given-names></name><name name-style="western"><surname>Menghetti</surname><given-names>C.</given-names></name><name name-style="western"><surname>Porta</surname><given-names>M.</given-names></name><name name-style="western"><surname>Servello</surname><given-names>D.</given-names></name></person-group><article-title>Safety in the use of dexmedetomidine (precedex) for deep brain stimulation surgery: Our experience in 23 randomized patients.</article-title><source>Neuromodulation</source><year>2013</year><volume>16</volume><issue>5</issue><fpage>401</fpage><lpage>406</lpage><pub-id pub-id-type="doi">10.1111/j.1525-1403.2012.00483.x</pub-id><pub-id pub-id-type="pmid">22780449</pub-id></element-citation></ref><ref id="r77"><label>77</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Morace</surname><given-names>R.</given-names></name><name name-style="western"><surname>De Angelis</surname><given-names>M.</given-names></name><name name-style="western"><surname>Aglialoro</surname><given-names>E.</given-names></name><name name-style="western"><surname>Maucione</surname><given-names>G.</given-names></name><name name-style="western"><surname>Cavallo</surname><given-names>L.</given-names></name><name name-style="western"><surname>Solari</surname><given-names>D.</given-names></name><name name-style="western"><surname>Modugno</surname><given-names>N.</given-names></name><name name-style="western"><surname>Santilli</surname><given-names>M.</given-names></name><name name-style="western"><surname>Esposito</surname><given-names>V.</given-names></name><name name-style="western"><surname>Aloj</surname><given-names>F.</given-names></name></person-group><article-title>Sedation with &#945;2 agonist dexmedetomidine during unilateral subthalamic nucleus deep brain stimulation: A preliminary report.</article-title><source>World Neurosurg.</source><year>2016</year><volume>89</volume><fpage>320</fpage><lpage>328</lpage><pub-id pub-id-type="doi">10.1016/j.wneu.2016.01.037</pub-id><pub-id pub-id-type="pmid">26805677</pub-id></element-citation></ref><ref id="r78"><label>78</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lombardo</surname><given-names>M.</given-names></name><name name-style="western"><surname>DiPiazza</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rippey</surname><given-names>K.</given-names></name><name name-style="western"><surname>Lubarr</surname><given-names>N.</given-names></name><name name-style="western"><surname>Clar</surname><given-names>E.</given-names></name><name name-style="western"><surname>Azmi</surname><given-names>H.</given-names></name></person-group><article-title>Treatment of acute delirium in a patient with Parkinson&#8217;s disease by transfer to the intensive care unit and administration of dexmedetomidine.</article-title><source>J. Mov. Disord.</source><year>2020</year><volume>13</volume><issue>2</issue><fpage>159</fpage><lpage>162</lpage><pub-id pub-id-type="doi">10.14802/jmd.20005</pub-id><pub-id pub-id-type="pmid">32498499</pub-id><pub-id pub-id-type="pmcid">PMC7280942</pub-id></element-citation></ref><ref id="r79"><label>79</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>T.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>M.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>Y.</given-names></name></person-group><article-title>Dexmedetomidine after deep brain stimulation for prevention of delirium in elderly patients with Parkinson&#8217;s disease: Protocol for a single-centre, randomised, double-blind, placebo-controlled trial in China.</article-title><source>BMJ Open</source><year>2023</year><volume>13</volume><issue>7</issue><fpage>e070185</fpage><pub-id pub-id-type="doi">10.1136/bmjopen-2022-070185</pub-id><pub-id pub-id-type="pmid">37433729</pub-id><pub-id pub-id-type="pmcid">PMC10347446</pub-id></element-citation></ref><ref id="r80"><label>80</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Asadi-Pooya</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Brigo</surname><given-names>F.</given-names></name><name name-style="western"><surname>Lattanzi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Blumcke</surname><given-names>I.</given-names></name></person-group><article-title>Adult epilepsy.</article-title><source>Lancet</source><year>2023</year><volume>402</volume><issue>10399</issue><fpage>412</fpage><lpage>424</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(23)01048-6</pub-id><pub-id pub-id-type="pmid">37459868</pub-id></element-citation></ref><ref id="r81"><label>81</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cetindag Ciltas</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ozdemir</surname><given-names>E.</given-names></name><name name-style="western"><surname>Gumus</surname><given-names>E.</given-names></name><name name-style="western"><surname>Taskiran</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Gunes</surname><given-names>H.</given-names></name><name name-style="western"><surname>Arslan</surname><given-names>G.</given-names></name></person-group><article-title>The anticonvulsant effects of alpha-2 adrenoceptor agonist dexmedetomidine on pentylenetetrazole-induced seizures in rats.</article-title><source>Neurochem. Res.</source><year>2022</year><volume>47</volume><issue>2</issue><fpage>305</fpage><lpage>314</lpage><pub-id pub-id-type="doi">10.1007/s11064-021-03445-4</pub-id><pub-id pub-id-type="pmid">34491515</pub-id></element-citation></ref><ref id="r82"><label>82</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mirski</surname><given-names>M.A.Z.</given-names></name><name name-style="western"><surname>Rossell</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>McPherson</surname><given-names>R.W.</given-names></name><name name-style="western"><surname>Traystman</surname><given-names>R.J.</given-names></name></person-group><article-title>Dexmedetomidine decreases seizure threshold in a rat model of experimental generalized epilepsy.</article-title><source>Anesthesiology</source><year>1994</year><volume>81</volume><issue>6</issue><fpage>1422</fpage><lpage>1428</lpage><pub-id pub-id-type="doi">10.1097/00000542-199412000-00017</pub-id><pub-id pub-id-type="pmid">7992911</pub-id></element-citation></ref><ref id="r83"><label>83</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chiu</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>T.Y.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>M.Y.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>C.W.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S.J.</given-names></name></person-group><article-title>Dexmedetomidine protects neurons from kainic acid-induced excitotoxicity by activating BDNF signaling.</article-title><source>Neurochem. Int.</source><year>2019</year><volume>129</volume><fpage>104493</fpage><pub-id pub-id-type="doi">10.1016/j.neuint.2019.104493</pub-id><pub-id pub-id-type="pmid">31220473</pub-id></element-citation></ref><ref id="r84"><label>84</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Treiman</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Walton</surname><given-names>N.Y.</given-names></name><name name-style="western"><surname>Kendrick</surname><given-names>C.</given-names></name></person-group><article-title>A progressive sequence of electroencephalographic changes during generalized convulsive status epilepticus.</article-title><source>Epilepsy Res.</source><year>1990</year><volume>5</volume><issue>1</issue><fpage>49</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1016/0920-1211(90)90065-4</pub-id><pub-id pub-id-type="pmid">2303022</pub-id></element-citation></ref><ref id="r85"><label>85</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fletcher</surname><given-names>A.</given-names></name><name name-style="western"><surname>Forster</surname><given-names>E.A.</given-names></name></person-group><article-title>A proconvulsant action of selective &#945;2-adrenoceptor antagonists.</article-title><source>Eur. J. Pharmacol.</source><year>1988</year><volume>151</volume><issue>1</issue><fpage>27</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1016/0014-2999(88)90688-7</pub-id><pub-id pub-id-type="pmid">2901362</pub-id></element-citation></ref><ref id="r86"><label>86</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sitnikova</surname><given-names>E.</given-names></name><name name-style="western"><surname>Pupikina</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rutskova</surname><given-names>E.</given-names></name></person-group><article-title>Alpha2 adrenergic modulation of spike-wave epilepsy: Experimental study of pro-epileptic and sedative effects of dexmedetomidine.</article-title><source>Int. J. Mol. Sci.</source><year>2023</year><volume>24</volume><issue>11</issue><fpage>9445</fpage><pub-id pub-id-type="doi">10.3390/ijms24119445</pub-id><pub-id pub-id-type="pmid">37298397</pub-id><pub-id pub-id-type="pmcid">PMC10254047</pub-id></element-citation></ref><ref id="r87"><label>87</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yavuz</surname><given-names>M.</given-names></name><name name-style="western"><surname>&#304;yik&#246;&#351;ker</surname><given-names>P.</given-names></name><name name-style="western"><surname>Mutlu</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kili&#231;parlar</surname><given-names>S.</given-names></name><name name-style="western"><surname>&#350;alci</surname><given-names>&#214;.H.</given-names></name><name name-style="western"><surname>Dolu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Kaymak&#231;ilar</surname><given-names>E.N.</given-names></name><name name-style="western"><surname>Akkol</surname><given-names>S.</given-names></name><name name-style="western"><surname>Onat</surname><given-names>F.</given-names></name></person-group><article-title>Dexmedetomidine,
an alpha 2A receptor agonist, triggers seizures unilaterally in
GAERS during the pre-epileptic phase: Does the onset of spikeand-
wave discharges occur in a focal manner?</article-title><source>Front. Neurol.</source><year>2023</year><volume>14</volume><fpage>1231736</fpage><pub-id pub-id-type="doi">10.3389/fneur.2023.1231736</pub-id><pub-id pub-id-type="pmid">38146441</pub-id><pub-id pub-id-type="pmcid">PMC10749324</pub-id></element-citation></ref><ref id="r88"><label>88</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Giorgi</surname><given-names>F.S.</given-names></name><name name-style="western"><surname>Pizzanelli</surname><given-names>C.</given-names></name><name name-style="western"><surname>Biagioni</surname><given-names>F.</given-names></name><name name-style="western"><surname>Murri</surname><given-names>L.</given-names></name><name name-style="western"><surname>Fornai</surname><given-names>F.</given-names></name></person-group><article-title>The role of norepinephrine in epilepsy: From the bench to the bedside.</article-title><source>Neurosci. Biobehav. Rev.</source><year>2004</year><volume>28</volume><issue>5</issue><fpage>507</fpage><lpage>524</lpage><pub-id pub-id-type="doi">10.1016/j.neubiorev.2004.06.008</pub-id><pub-id pub-id-type="pmid">15465138</pub-id></element-citation></ref><ref id="r89"><label>89</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jurgens</surname><given-names>C.W.D.</given-names></name></person-group><article-title>Hammad, H.M.; Lichter, J.A.; Boese, S.J.; Nelson, B.W.; Goldenstein, B.L.; Davis, K.L.; Xu, K.; Hillman, K.L.; Porter, J.E.; Doze, V.A. &#945;2A adrenergic receptor activation inhibits epileptiform activity in the rat hippocampal CA3 region.</article-title><source>Mol. Pharmacol.</source><year>2007</year><volume>71</volume><issue>6</issue><fpage>1572</fpage><lpage>1581</lpage><pub-id pub-id-type="doi">10.1124/mol.106.031773</pub-id><pub-id pub-id-type="pmid">17341653</pub-id></element-citation></ref><ref id="r90"><label>90</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tenney</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Rose</surname><given-names>D.F.</given-names></name></person-group><article-title>Intranasal dexmedetomidine for sedation during magnetoencephalography.</article-title><source>J. Clin. Neurophysiol.</source><year>2019</year><volume>36</volume><issue>5</issue><fpage>371</fpage><lpage>374</lpage><pub-id pub-id-type="doi">10.1097/WNP.0000000000000602</pub-id><pub-id pub-id-type="pmid">31107715</pub-id></element-citation></ref><ref id="r91"><label>91</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tewari</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mahmoud</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rose</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ding</surname><given-names>L.</given-names></name><name name-style="western"><surname>Tenney</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cravero</surname><given-names>J.</given-names></name></person-group><article-title>Intravenous dexmedetomidine sedation for magnetoencephalography: A retrospective study.</article-title><source>Paediatr. Anaesth.</source><year>2020</year><volume>30</volume><issue>7</issue><fpage>799</fpage><lpage>805</lpage><pub-id pub-id-type="doi">10.1111/pan.13925</pub-id><pub-id pub-id-type="pmid">32436319</pub-id></element-citation></ref><ref id="r92"><label>92</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chaitanya</surname><given-names>G.</given-names></name><name name-style="western"><surname>Arivazhagan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sinha</surname><given-names>S.</given-names></name><name name-style="western"><surname>Reddy</surname><given-names>K.R.M.</given-names></name><name name-style="western"><surname>Thennarasu</surname><given-names>K.</given-names></name><name name-style="western"><surname>Bharath</surname><given-names>R.D.</given-names></name><name name-style="western"><surname>Rao</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>Chandramouli</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Satishchandra</surname><given-names>P.</given-names></name></person-group><article-title>Dexmedetomidine anesthesia enhances spike generation during intra-operative electrocorticography: A promising adjunct for epilepsy surgery.</article-title><source>Epilepsy Res.</source><year>2015</year><volume>109</volume><fpage>65</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1016/j.eplepsyres.2014.10.006</pub-id><pub-id pub-id-type="pmid">25524844</pub-id></element-citation></ref><ref id="r93"><label>93</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jung</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Noh</surname><given-names>J.</given-names></name></person-group><article-title>Sex differential effect of dexmedetomidine on fear memory extinction and anxiety behavior in adolescent rats.</article-title><source>Neurosci. Res.</source><year>2019</year><volume>149</volume><fpage>29</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1016/j.neures.2019.01.006</pub-id><pub-id pub-id-type="pmid">30685494</pub-id></element-citation></ref><ref id="r94"><label>94</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qiu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>P.</given-names></name><name name-style="western"><surname>Rao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Qing</surname><given-names>X.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Mei</surname><given-names>B.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name></person-group><article-title>Dexmedetomidine inhibits paraventricular corticotropin-releasing hormone neurons that attenuate acute stress-induced anxiety-like behavior in mice.</article-title><source>Anesthesiology</source><year>2024</year><volume>140</volume><issue>6</issue><fpage>1134</fpage><lpage>1152</lpage><pub-id pub-id-type="doi">10.1097/ALN.0000000000004982</pub-id><pub-id pub-id-type="pmid">38498811</pub-id></element-citation></ref><ref id="r95"><label>95</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lim</surname><given-names>Y.P.</given-names></name><name name-style="western"><surname>Yahya</surname><given-names>N.</given-names></name><name name-style="western"><surname>Izaham</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kamaruzaman</surname><given-names>E.</given-names></name><name name-style="western"><surname>Zainuddin</surname><given-names>M.Z.</given-names></name><name name-style="western"><surname>Wan Mat</surname><given-names>W.R.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>S.S.P.</given-names></name><name name-style="western"><surname>Md Zain</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mahdi</surname><given-names>M.S.N.</given-names></name></person-group><article-title>The comparison between propofol and dexmedetomidine infusion on perioperative anxiety during regional anesthesia.</article-title><source>Turk. J. Med. Sci.</source><year>2018</year><volume>48</volume><issue>6</issue><fpage>1219</fpage><lpage>1227</lpage><pub-id pub-id-type="doi">10.3906/sag-1802-126</pub-id><pub-id pub-id-type="pmid">30541250</pub-id></element-citation></ref><ref id="r96"><label>96</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>L.P.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>W.</given-names></name></person-group><article-title>Effect of dexmedetomidine for sedation and cognitive function in patients with preoperative anxiety undergoing carotid artery stenting.</article-title><source>J. Int. Med. Res.</source><year>2020</year><volume>48</volume><issue>9</issue><fpage>0300060520938959</fpage><pub-id pub-id-type="doi">10.1177/0300060520938959</pub-id><pub-id pub-id-type="pmid">32972265</pub-id><pub-id pub-id-type="pmcid">PMC7522831</pub-id></element-citation></ref><ref id="r97"><label>97</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Han</surname><given-names>J.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>Y.J.</given-names></name><name name-style="western"><surname>Pu</surname><given-names>C.X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name></person-group><article-title>Comparative study of the efficacy of dexmedetomidine and fentanyl on anxiety and pain of parturients with different COMTva1158met genotypes.</article-title><source>BMC Anesthesiol.</source><year>2022</year><volume>22</volume><issue>1</issue><fpage>84</fpage><pub-id pub-id-type="doi">10.1186/s12871-022-01628-2</pub-id><pub-id pub-id-type="pmid">35346044</pub-id><pub-id pub-id-type="pmcid">PMC8962552</pub-id></element-citation></ref><ref id="r98"><label>98</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Loh</surname><given-names>P.S.</given-names></name><name name-style="western"><surname>Ariffin</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Rai</surname><given-names>V.</given-names></name><name name-style="western"><surname>Lai</surname><given-names>L.L.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ramli</surname><given-names>N.</given-names></name></person-group><article-title>Comparing the efficacy and safety between propofol and dexmedetomidine for sedation in claustrophobic adults undergoing magnetic resonance imaging (PADAM trial).</article-title><source>J. Clin. Anesth.</source><year>2016</year><volume>34</volume><fpage>216</fpage><lpage>222</lpage><pub-id pub-id-type="doi">10.1016/j.jclinane.2016.03.074</pub-id><pub-id pub-id-type="pmid">27687378</pub-id></element-citation></ref><ref id="r99"><label>99</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Du</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.Y.</given-names></name><name name-style="western"><surname>Qu</surname><given-names>S.Q.</given-names></name><name name-style="western"><surname>Song</surname><given-names>Z.B.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>S.W.</given-names></name><name name-style="western"><surname>Xiang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Q.L.</given-names></name><name name-style="western"><surname>Cravero</surname><given-names>J.</given-names></name></person-group><article-title>The comparison of dexmedetomidine and midazolam premedication on postoperative anxiety in children for hernia repair surgery: A randomized controlled trial.</article-title><source>Paediatr. Anaesth.</source><year>2019</year><volume>29</volume><issue>8</issue><fpage>843</fpage><lpage>849</lpage><pub-id pub-id-type="doi">10.1111/pan.13667</pub-id><pub-id pub-id-type="pmid">31125470</pub-id><pub-id pub-id-type="pmcid">PMC6852055</pub-id></element-citation></ref><ref id="r100"><label>100</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Ruan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>Y.</given-names></name></person-group><article-title>Major depressive disorder: Advances in neuroscience research and translational applications.</article-title><source>Neurosci. Bull.</source><year>2021</year><volume>37</volume><issue>6</issue><fpage>863</fpage><lpage>880</lpage><pub-id pub-id-type="doi">10.1007/s12264-021-00638-3</pub-id><pub-id pub-id-type="pmid">33582959</pub-id><pub-id pub-id-type="pmcid">PMC8192601</pub-id></element-citation></ref><ref id="r101"><label>101</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kessler</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>Berglund</surname><given-names>P.</given-names></name><name name-style="western"><surname>Demler</surname><given-names>O.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>R.</given-names></name><name name-style="western"><surname>Koretz</surname><given-names>D.</given-names></name><name name-style="western"><surname>Merikangas</surname><given-names>K.R.</given-names></name><name name-style="western"><surname>Rush</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Walters</surname><given-names>E.E.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>P.S.</given-names></name></person-group><article-title>The epidemiology of major depressive disorder: Results from the National Comorbidity Survey Replication (NCS-R).</article-title><source>JAMA</source><year>2003</year><volume>289</volume><issue>23</issue><fpage>3095</fpage><lpage>3105</lpage><pub-id pub-id-type="doi">10.1001/jama.289.23.3095</pub-id><pub-id pub-id-type="pmid">12813115</pub-id></element-citation></ref><ref id="r102"><label>102</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lim</surname><given-names>G.Y.</given-names></name><name name-style="western"><surname>Tam</surname><given-names>W.W.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ho</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>M.W.</given-names></name><name name-style="western"><surname>Ho</surname><given-names>R.C.</given-names></name></person-group><article-title>Prevalence of depression in the community from 30 countries between 1994 and 2014.</article-title><source>Sci. Rep.</source><year>2018</year><volume>8</volume><issue>1</issue><fpage>2861</fpage><pub-id pub-id-type="doi">10.1038/s41598-018-21243-x</pub-id><pub-id pub-id-type="pmid">29434331</pub-id><pub-id pub-id-type="pmcid">PMC5809481</pub-id></element-citation></ref><ref id="r103"><label>103</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gold</surname><given-names>P.W.</given-names></name><name name-style="western"><surname>Machado-Vieira</surname><given-names>R.</given-names></name><name name-style="western"><surname>Pavlatou</surname><given-names>M.G.</given-names></name></person-group><article-title>Clinical and biochemical manifestations of depression: Relation to the neurobiology of stress.</article-title><source>Neural Plast.</source><year>2015</year><volume>2015</volume><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1155/2015/581976</pub-id><pub-id pub-id-type="pmid">25878903</pub-id><pub-id pub-id-type="pmcid">PMC4387963</pub-id></element-citation></ref><ref id="r104"><label>104</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dunlop</surname><given-names>B.W.</given-names></name><name name-style="western"><surname>Nemeroff</surname><given-names>C.B.</given-names></name></person-group><article-title>The role of dopamine in the pathophysiology of depression.</article-title><source>Arch. Gen. Psychiatry</source><year>2007</year><volume>64</volume><issue>3</issue><fpage>327</fpage><lpage>337</lpage><pub-id pub-id-type="doi">10.1001/archpsyc.64.3.327</pub-id><pub-id pub-id-type="pmid">17339521</pub-id></element-citation></ref><ref id="r105"><label>105</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moon</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Ko</surname><given-names>I.G.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Hwang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>An</surname><given-names>H.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Yi</surname><given-names>J.W.</given-names></name></person-group><article-title>Dexmedetomidine ameliorates sleep deprivation-induced depressive behaviors in mice.</article-title><source>Int. Neurourol. J.</source><year>2018</year><volume>22</volume><issue>Suppl. 3</issue><fpage>S139</fpage><lpage>S146</lpage><pub-id pub-id-type="doi">10.5213/inj.1836228.114</pub-id><pub-id pub-id-type="pmid">30396263</pub-id><pub-id pub-id-type="pmcid">PMC6234724</pub-id></element-citation></ref><ref id="r106"><label>106</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>He</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name></person-group><article-title>A new potential antidepressant: Dexmedetomidine alleviates neuropathic pain-induced depression by increasing neurogenesis in the hippocampus.</article-title><source>Pharmacology</source><year>2022</year><volume>107</volume><issue>5-6</issue><fpage>317</fpage><lpage>329</lpage><pub-id pub-id-type="doi">10.1159/000521737</pub-id><pub-id pub-id-type="pmid">35196664</pub-id></element-citation></ref><ref id="r107"><label>107</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pancaro</surname><given-names>C.</given-names></name><name name-style="western"><surname>Segal</surname><given-names>B.S.</given-names></name><name name-style="western"><surname>Sikes</surname><given-names>R.W.</given-names></name><name name-style="western"><surname>Almeer</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Schumann</surname><given-names>R.</given-names></name><name name-style="western"><surname>Azocar</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Marchand</surname><given-names>J.E.</given-names></name></person-group><article-title>Dexmedetomidine and ketamine show distinct patterns of cell degeneration and apoptosis in the developing rat neonatal brain.</article-title><source>J. Matern. Fetal Neonatal Med.</source><year>2016</year><volume>29</volume><issue>23</issue><fpage>3827</fpage><lpage>3833</lpage><pub-id pub-id-type="doi">10.3109/14767058.2016.1148132</pub-id><pub-id pub-id-type="pmid">26821538</pub-id></element-citation></ref><ref id="r108"><label>108</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhuang</surname><given-names>F.Z.</given-names></name><name name-style="western"><surname>Qin</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>Q.F.</given-names></name><name name-style="western"><surname>Li</surname><given-names>M.</given-names></name><name name-style="western"><surname>Villarreal</surname><given-names>M.</given-names></name><name name-style="western"><surname>Benefield</surname><given-names>L.</given-names></name><name name-style="western"><surname>Gu</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>T.F.</given-names></name></person-group><article-title>Dexmedetomidine protects against learning and memory impairments caused by electroconvulsive shock in depressed rats: Involvement of the NMDA receptor subunit 2B (NR2B)-ERK signaling pathway.</article-title><source>Psychiatry Res.</source><year>2016</year><volume>243</volume><fpage>446</fpage><lpage>452</lpage><pub-id pub-id-type="doi">10.1016/j.psychres.2016.07.020</pub-id><pub-id pub-id-type="pmid">27455425</pub-id></element-citation></ref><ref id="r109"><label>109</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shams</surname><given-names>T.</given-names></name><name name-style="western"><surname>El-Masry</surname><given-names>R.</given-names></name></person-group><article-title>Ketofol-Dexmedetomidine combination in ECT: A punch for depression and agitation.</article-title><source>Indian J. Anaesth.</source><year>2014</year><volume>58</volume><issue>3</issue><fpage>275</fpage><lpage>280</lpage><pub-id pub-id-type="doi">10.4103/0019-5049.135037</pub-id><pub-id pub-id-type="pmid">25024469</pub-id><pub-id pub-id-type="pmcid">PMC4090992</pub-id></element-citation></ref><ref id="r110"><label>110</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>H.Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S.Y.</given-names></name><name name-style="western"><surname>Quan</surname><given-names>C.X.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Li</surname><given-names>D.Y.</given-names></name><name name-style="western"><surname>Zhen</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Duan</surname><given-names>K.M.</given-names></name></person-group><article-title>Dexmedetomidine alleviates postpartum depressive symptoms following cesarean section in chinese women: A randomized placebo-controlled study.</article-title><source>Pharmacotherapy</source><year>2019</year><volume>39</volume><issue>10</issue><fpage>994</fpage><lpage>1004</lpage><pub-id pub-id-type="doi">10.1002/phar.2320</pub-id><pub-id pub-id-type="pmid">31411762</pub-id></element-citation></ref><ref id="r111"><label>111</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Bai</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Li</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ping</surname><given-names>A.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Duan</surname><given-names>K.</given-names></name></person-group><article-title>Effect of dexmedetomidine on postpartum depression in women with prenatal depression.</article-title><source>JAMA Netw. Open</source><year>2024</year><volume>7</volume><issue>1</issue><fpage>e2353252</fpage><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2023.53252</pub-id><pub-id pub-id-type="pmid">38270949</pub-id><pub-id pub-id-type="pmcid">PMC10811555</pub-id></element-citation></ref><ref id="r112"><label>112</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Li</surname><given-names>W.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Han</surname><given-names>L.</given-names></name><name name-style="western"><surname>Mao</surname><given-names>H.</given-names></name><name name-style="western"><surname>Cai</surname><given-names>F.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>R.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name></person-group><article-title>Antidepressant effects of dexmedetomidine compared with ECT in patients with treatment-resistant depression.</article-title><source>J. Affect. Disord.</source><year>2024</year><volume>347</volume><fpage>437</fpage><lpage>444</lpage><pub-id pub-id-type="doi">10.1016/j.jad.2023.11.077</pub-id><pub-id pub-id-type="pmid">38000472</pub-id></element-citation></ref><ref id="r113"><label>113</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reade</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Eastwood</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>Bellomo</surname><given-names>R.</given-names></name><name name-style="western"><surname>Bailey</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bersten</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cheung</surname><given-names>B.</given-names></name><name name-style="western"><surname>Davies</surname><given-names>A.</given-names></name><name name-style="western"><surname>Delaney</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ghosh</surname><given-names>A.</given-names></name><name name-style="western"><surname>van Haren</surname><given-names>F.</given-names></name><name name-style="western"><surname>Harley</surname><given-names>N.</given-names></name><name name-style="western"><surname>Knight</surname><given-names>D.</given-names></name><name name-style="western"><surname>McGuiness</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mulder</surname><given-names>J.</given-names></name><name name-style="western"><surname>O&#8217;Donoghue</surname><given-names>S.</given-names></name><name name-style="western"><surname>Simpson</surname><given-names>N.</given-names></name><name name-style="western"><surname>Young</surname><given-names>P.</given-names></name></person-group><article-title>Effect of dexmedetomidine added to standard care on ventilator-free time in patients with agitated delirium.</article-title><source>JAMA</source><year>2016</year><volume>315</volume><issue>14</issue><fpage>1460</fpage><lpage>1468</lpage><pub-id pub-id-type="doi">10.1001/jama.2016.2707</pub-id><pub-id pub-id-type="pmid">26975647</pub-id></element-citation></ref><ref id="r114"><label>114</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ward</surname><given-names>K.</given-names></name><name name-style="western"><surname>Citrome</surname><given-names>L.</given-names></name></person-group><article-title>The treatment of acute agitation associated with schizophrenia or bipolar disorder: Investigational drugs in early stages of their clinical development, and their clinical context and potential place in therapy.</article-title><source>Expert Opin. Investig. Drugs</source><year>2020</year><volume>29</volume><issue>3</issue><fpage>245</fpage><lpage>257</lpage><pub-id pub-id-type="doi">10.1080/13543784.2020.1727884</pub-id><pub-id pub-id-type="pmid">32031021</pub-id></element-citation></ref><ref id="r115"><label>115</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Preskorn</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Zeller</surname><given-names>S.</given-names></name><name name-style="western"><surname>Citrome</surname><given-names>L.</given-names></name><name name-style="western"><surname>Finman</surname><given-names>J.</given-names></name><name name-style="western"><surname>Goldberg</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Fava</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kakar</surname><given-names>R.</given-names></name><name name-style="western"><surname>De Vivo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yocca</surname><given-names>F.D.</given-names></name><name name-style="western"><surname>Risinger</surname><given-names>R.</given-names></name></person-group><article-title>Effect of sublingual dexmedetomidine vs. placebo on acute agitation associated with bipolar disorder.</article-title><source>JAMA</source><year>2022</year><volume>327</volume><issue>8</issue><fpage>727</fpage><lpage>736</lpage><pub-id pub-id-type="doi">10.1001/jama.2022.0799</pub-id><pub-id pub-id-type="pmid">35191924</pub-id><pub-id pub-id-type="pmcid">PMC8864508</pub-id></element-citation></ref><ref id="r116"><label>116</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Csernansky</surname><given-names>J.G.</given-names></name><name name-style="western"><surname>Mahmoud</surname><given-names>R.</given-names></name><name name-style="western"><surname>Brenner</surname><given-names>R.</given-names></name></person-group><article-title>A comparison of risperidone and haloperidol for the prevention of relapse in patients with Schizophrenia.</article-title><source>N. Engl. J. Med.</source><year>2002</year><volume>346</volume><issue>1</issue><fpage>16</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa002028</pub-id><pub-id pub-id-type="pmid">11777998</pub-id></element-citation></ref><ref id="r117"><label>117</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Skrupky</surname><given-names>L.P.</given-names></name><name name-style="western"><surname>Drewry</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Wessman</surname><given-names>B.</given-names></name><name name-style="western"><surname>Field</surname><given-names>R.R.</given-names></name><name name-style="western"><surname>Fagley</surname><given-names>R.E.</given-names></name><name name-style="western"><surname>Varghese</surname><given-names>L.</given-names></name><name name-style="western"><surname>Lieu</surname><given-names>A.</given-names></name><name name-style="western"><surname>Olatunde</surname><given-names>J.</given-names></name><name name-style="western"><surname>Micek</surname><given-names>S.T.</given-names></name><name name-style="western"><surname>Kollef</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Boyle</surname><given-names>W.A.</given-names></name></person-group><article-title>Clinical effectiveness of a sedation protocol minimizing benzodiazepine infusions and favoring early dexmedetomidine: A before-after study.</article-title><source>Crit. Care</source><year>2015</year><volume>19</volume><issue>1</issue><fpage>136</fpage><pub-id pub-id-type="doi">10.1186/s13054-015-0874-0</pub-id><pub-id pub-id-type="pmid">25887495</pub-id><pub-id pub-id-type="pmcid">PMC4403893</pub-id></element-citation></ref><ref id="r118"><label>118</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zeller</surname><given-names>S.</given-names></name><name name-style="western"><surname>Citrome</surname><given-names>L.</given-names></name></person-group><article-title>Managing agitation associated with schizophrenia and bipolar disorder in the emergency setting.</article-title><source>West. J. Emerg. Med.</source><year>2016</year><volume>17</volume><issue>2</issue><fpage>165</fpage><lpage>172</lpage><pub-id pub-id-type="doi">10.5811/westjem.2015.12.28763</pub-id><pub-id pub-id-type="pmid">26973742</pub-id><pub-id pub-id-type="pmcid">PMC4786236</pub-id></element-citation></ref><ref id="r119"><label>119</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gerrits</surname><given-names>M.</given-names></name><name name-style="western"><surname>de Greef</surname><given-names>R.</given-names></name><name name-style="western"><surname>Peeters</surname><given-names>P.</given-names></name></person-group><article-title>Effect of absorption site on the pharmacokinetics of sublingual asenapine in healthy male subjects.</article-title><source>Biopharm. Drug Dispos.</source><year>2010</year><volume>31</volume><issue>5-6</issue><fpage>351</fpage><lpage>357</lpage><pub-id pub-id-type="doi">10.1002/bdd.718</pub-id><pub-id pub-id-type="pmid">20549835</pub-id></element-citation></ref><ref id="r120"><label>120</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cao</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Xiong</surname><given-names>L.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>C.</given-names></name></person-group><article-title>Automated phenotyping of postoperative delirium-like behaviour in mice reveals the therapeutic efficacy of dexmedetomidine.</article-title><source>Commun. Biol.</source><year>2023</year><volume>6</volume><issue>1</issue><fpage>807</fpage><pub-id pub-id-type="doi">10.1038/s42003-023-05149-7</pub-id><pub-id pub-id-type="pmid">37532767</pub-id><pub-id pub-id-type="pmcid">PMC10397202</pub-id></element-citation></ref><ref id="r121"><label>121</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>W.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>K.</given-names></name></person-group><article-title>The application of extended reality in treating children with Autism Spectrum Disorder.</article-title><source>Neurosci. Bull.</source><year>2024</year><volume>40</volume><issue>8</issue><fpage>1189</fpage><lpage>1204</lpage><pub-id pub-id-type="doi">10.1007/s12264-024-01190-6</pub-id><pub-id pub-id-type="pmid">38498091</pub-id><pub-id pub-id-type="pmcid">PMC11306495</pub-id></element-citation></ref><ref id="r122"><label>122</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liang</surname><given-names>Z.K.</given-names></name><name name-style="western"><surname>Xiong</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zou</surname><given-names>X.</given-names></name><name name-style="western"><surname>Mai</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>B.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>C.</given-names></name><name name-style="western"><surname>Xin</surname><given-names>W.J.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>D.X.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>T.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>X.</given-names></name></person-group><article-title>Resolving neuroinflammatory and social deficits in ASD model mice: Dexmedetomidine downregulates NF-&#954;B/IL-6 pathway <italic toggle="yes">via</italic> &#945;2AR.</article-title><source>Brain Behav. Immun.</source><year>2024</year><volume>119</volume><fpage>84</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1016/j.bbi.2024.03.040</pub-id><pub-id pub-id-type="pmid">38552922</pub-id></element-citation></ref><ref id="r123"><label>123</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luque</surname><given-names>C.G.</given-names></name><name name-style="western"><surname>Atkins-Labelle</surname><given-names>C.</given-names></name><name name-style="western"><surname>Pauwels</surname><given-names>J.</given-names></name><name name-style="western"><surname>Costello</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kozak</surname><given-names>F.K.</given-names></name><name name-style="western"><surname>Chadha</surname><given-names>N.K.</given-names></name></person-group><article-title>Intranasal Dexmedetomidine increases the successful sedation of children with Autism for out-patient auditory brainstem response hearing tests.</article-title><source>Int. J. Pediatr. Otorhinolaryngol.</source><year>2021</year><volume>151</volume><fpage>110945</fpage><pub-id pub-id-type="doi">10.1016/j.ijporl.2021.110945</pub-id><pub-id pub-id-type="pmid">34736008</pub-id></element-citation></ref><ref id="r124"><label>124</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kenneally</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cummins</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bailey</surname><given-names>A.</given-names></name><name name-style="western"><surname>Yackey</surname><given-names>K.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>L.</given-names></name><name name-style="western"><surname>Carter</surname><given-names>C.</given-names></name><name name-style="western"><surname>Dugan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Baum</surname><given-names>R.A.</given-names></name></person-group><article-title>Intranasal dexmedetomidine use in pediatric patients for anxiolysis in the emergency department.</article-title><source>Pediatr. Emerg. Care</source><year>2023</year><volume>39</volume><issue>9</issue><fpage>685</fpage><lpage>691</lpage><pub-id pub-id-type="doi">10.1097/PEC.0000000000002901</pub-id><pub-id pub-id-type="pmid">36728557</pub-id></element-citation></ref><ref id="r125"><label>125</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaplan</surname><given-names>E.</given-names></name><name name-style="western"><surname>Shifeldrim</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kraus</surname><given-names>D.</given-names></name><name name-style="western"><surname>Weissbach</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kadmon</surname><given-names>G.</given-names></name><name name-style="western"><surname>Milkh</surname><given-names>R.</given-names></name><name name-style="western"><surname>Nahum</surname><given-names>E.</given-names></name></person-group><article-title>Intranasal dexmedetomidine vs. oral triclofos sodium for sedation of children with autism undergoing electroencephalograms.</article-title><source>Eur. J. Paediatr. Neurol.</source><year>2022</year><volume>37</volume><fpage>19</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1016/j.ejpn.2022.01.005</pub-id><pub-id pub-id-type="pmid">35016051</pub-id></element-citation></ref><ref id="r126"><label>126</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dutta</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lal</surname><given-names>R.</given-names></name><name name-style="western"><surname>Karol</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ebert</surname><given-names>T.</given-names></name></person-group><article-title>Influence of cardiac output on dexmedetomidine pharmacokinetics.</article-title><source>J. Pharm. Sci.</source><year>2000</year><volume>89</volume><issue>4</issue><fpage>519</fpage><lpage>527</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/(SICI)1520-6017(200004)89:4&amp;#x0003c;519::AID-JPS9&amp;#x0003e;3.0.CO;2-U</pub-id><pub-id pub-id-type="pmid">10737913</pub-id></element-citation></ref><ref id="r127"><label>127</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Keating</surname><given-names>G.M.</given-names></name></person-group><article-title>Dexmedetomidine: A review of its use for sedation in the intensive care setting.</article-title><source>Drugs</source><year>2015</year><volume>75</volume><issue>10</issue><fpage>1119</fpage><lpage>1130</lpage><pub-id pub-id-type="doi">10.1007/s40265-015-0419-5</pub-id><pub-id pub-id-type="pmid">26063213</pub-id></element-citation></ref><ref id="r128"><label>128</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jang</surname><given-names>Y.E.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>Y.C.</given-names></name><name name-style="western"><surname>Yoon</surname><given-names>H.K.</given-names></name><name name-style="western"><surname>Jeon</surname><given-names>Y.T.</given-names></name><name name-style="western"><surname>Hwang</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>E.</given-names></name><name name-style="western"><surname>Park</surname><given-names>H.P.</given-names></name></person-group><article-title>A randomized controlled trial of the effect of preoperative dexmedetomidine on the half maximal effective concentration of propofol for successful i-gel insertion without muscle relaxants.</article-title><source>J. Anesth.</source><year>2015</year><volume>29</volume><issue>3</issue><fpage>338</fpage><lpage>345</lpage><pub-id pub-id-type="doi">10.1007/s00540-014-1949-9</pub-id><pub-id pub-id-type="pmid">25394762</pub-id></element-citation></ref><ref id="r129"><label>129</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>W.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>W.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Ling</surname><given-names>H.</given-names></name><name name-style="western"><surname>Gan</surname><given-names>X.</given-names></name></person-group><article-title>Efficacy of premedication with intranasal dexmedetomidine on inhalational induction and postoperative emergence agitation in pediatric undergoing cataract surgery with sevoflurane.</article-title><source>J. Clin. Anesth.</source><year>2016</year><volume>33</volume><fpage>289</fpage><lpage>295</lpage><pub-id pub-id-type="doi">10.1016/j.jclinane.2016.04.027</pub-id><pub-id pub-id-type="pmid">27555179</pub-id></element-citation></ref><ref id="r130"><label>130</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zanaty</surname><given-names>O.M.</given-names></name><name name-style="western"><surname>El Metainy</surname><given-names>S.A.</given-names></name></person-group><article-title>A comparative evaluation of nebulized dexmedetomidine, nebulized ketamine, and their combination as premedication for outpatient pediatric dental surgery.</article-title><source>Anesth. Analg.</source><year>2015</year><volume>121</volume><issue>1</issue><fpage>167</fpage><lpage>171</lpage><pub-id pub-id-type="doi">10.1213/ANE.0000000000000728</pub-id><pub-id pub-id-type="pmid">25822924</pub-id></element-citation></ref><ref id="r131"><label>131</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xing</surname><given-names>F.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>T.T.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Qu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Xing</surname><given-names>N.</given-names></name></person-group><article-title>Comparison of dexmedetomidine and a dexmedetomidine-esketamine combination for reducing dental anxiety in preschool children undergoing dental treatment under general anesthesia: A randomized controlled trial.</article-title><source>J. Affect. Disord.</source><year>2024</year><volume>347</volume><fpage>569</fpage><lpage>575</lpage><pub-id pub-id-type="doi">10.1016/j.jad.2023.12.011</pub-id><pub-id pub-id-type="pmid">38065480</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="F1" fig-type="figure" orientation="portrait"><label>Fig. (1)</label><caption><p>The mechanism of dex in treating neuropsychiatric disorders in the central nervous system. The therapeutic mechanism of Dex in addressing neuropsychiatric disorders encompasses various brain regions, such as the HIP, ACC, PrL, PVH, STR, and LC. Dex exerts an inhibitory effect on neuronal hyperactivity, thereby offering treatment benefits for several neuropsychiatric disorders, including AD, PD, ASD, anxiety, epilepsy, and depressive disorders. In glia, Dex demonstrates effective prevention of astrocyte pyroptosis, inhibition of microglial overactivation, and promotion of M2 microglia polarization, consequently diminishing the production of pro-inflammatory factors.</p><p><bold>Abbreviations:</bold> &#945;2AR, &#945;2 adrenergic receptor; Dex, dexmedetomidine; HIP, hippocampus; ACC, anterior cingulate cortex; PrL, prelimbic cortex; PVH, hypothalamic paraventricular; STR, striatum; LC, locus coeruleus; AD, Alzheimer&#8217;s disease; PD, Parkinson&#8217;s disease; ASD, autism spectrum disorders; BDNF, Brain-derived neurotrophic factor.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="CN-23-8-929_F1.jpg"/></fig><table-wrap position="float" id="T1" orientation="portrait"><label>Table 1</label><caption><p>Preclinical studies of Dex in neuropsychiatric diseases.</p></caption><table frame="border" rules="all" width="100%"><thead><tr><th valign="middle" align="center" scope="col" rowspan="1" colspan="1">
<bold>Diseases</bold>
</th><th valign="middle" align="center" scope="col" rowspan="1" colspan="1">
<bold>Study Model</bold>
</th><th valign="middle" align="center" scope="col" rowspan="1" colspan="1">
<bold>Therapeutic Regimen (Dex)</bold>
</th><th valign="middle" align="center" scope="col" rowspan="1" colspan="1">
<bold>Main Findings</bold>
</th><th valign="middle" align="center" scope="col" rowspan="1" colspan="1">
<bold>References</bold>
</th></tr></thead><tbody><tr><td valign="middle" align="center" scope="row" rowspan="1" colspan="1">AD</td><td valign="middle" align="center" rowspan="1" colspan="1">AD mice model induced by A&#946; injection or 5 x FAD mice</td><td valign="middle" align="center" rowspan="1" colspan="1">i.p. (20 or 100 &#956;g/kg) for several days</td><td valign="middle" align="center" rowspan="1" colspan="1">Dex slowed the progression of AD and improve its cognitive deficits.</td><td valign="middle" align="center" rowspan="1" colspan="1">[<xref rid="r51" ref-type="bibr">51</xref>-<xref rid="r55" ref-type="bibr">55</xref>]</td></tr><tr><td valign="middle" align="center" scope="row" rowspan="1" colspan="1">PD</td><td valign="middle" align="center" rowspan="1" colspan="1">PD mice model-induced by MPTP</td><td valign="middle" align="center" rowspan="1" colspan="1">i.p. (2~50 &#956;g/kg) for several days</td><td valign="middle" align="center" rowspan="1" colspan="1">Dex inhibits inflammation and the degeneration of dopamine neurons.</td><td valign="middle" align="center" rowspan="1" colspan="1">[<xref rid="r64" ref-type="bibr">64</xref>-<xref rid="r65" ref-type="bibr">65</xref>]</td></tr><tr><td valign="middle" align="center" scope="row" rowspan="1" colspan="1">Epilepsy</td><td valign="middle" align="center" rowspan="1" colspan="1">Epilepsy rats model induced by PTZ or GAERS rats.</td><td valign="middle" align="center" rowspan="1" colspan="1">i.p.; 100~500 &#956;g/kg</td><td valign="middle" align="center" rowspan="1" colspan="1">Dex provided a dual benefit of seizure control and neuroprotection.</td><td valign="middle" align="center" rowspan="1" colspan="1">[<xref rid="r81" ref-type="bibr">81</xref>-<xref rid="r87" ref-type="bibr">87</xref>]</td></tr><tr><td valign="middle" align="center" scope="row" rowspan="1" colspan="1">Anxiety</td><td valign="middle" align="center" rowspan="1" colspan="1">PTSD or SDS model</td><td valign="middle" align="center" rowspan="1" colspan="1">i.p.; 20 or 40 &#956;g/kg</td><td valign="middle" align="center" rowspan="1" colspan="1">Dex effectively alleviated anxiety levels.</td><td valign="middle" align="center" rowspan="1" colspan="1">[<xref rid="r93" ref-type="bibr">93</xref>-<xref rid="r94" ref-type="bibr">94</xref>]</td></tr><tr><td valign="middle" align="center" scope="row" rowspan="1" colspan="1">Depressive disorders</td><td valign="middle" align="center" rowspan="1" colspan="1">Sleep deprivation or CCI mice model</td><td valign="middle" align="center" rowspan="1" colspan="1">i.p. (0.5~25 &#956;g/kg) for several days</td><td valign="middle" align="center" rowspan="1" colspan="1">Dex significantly abated depression-like behavior and normalized dopamine release.</td><td valign="middle" align="center" rowspan="1" colspan="1">[<xref rid="r105" ref-type="bibr">105</xref>-<xref rid="r106" ref-type="bibr">106</xref>]</td></tr><tr><td valign="middle" align="center" scope="row" rowspan="1" colspan="1">ASD</td><td valign="middle" align="center" rowspan="1" colspan="1">BTBR mice</td><td valign="middle" align="center" rowspan="1" colspan="1">i.p. (0.8 &#956;g) for several days</td><td valign="middle" align="center" rowspan="1" colspan="1">Dex treated social disorders and stereotyped behavior in BTBR mice.</td><td valign="middle" align="center" rowspan="1" colspan="1">[<xref rid="r122" ref-type="bibr">122</xref>]</td></tr></tbody></table><table-wrap-foot><p><bold>Abbreviations</bold>: A&#946;: &#946;-amyloid MPTP: methyl-4-phenyl-1,2,3,6-tetrahydropyridine i.p.: intraperitoneal injection, PTSD: Post-Traumatic Stress Disorder SDS: social defeat stress CCI: chronic constrictive injury, Dex: dexmedetomidine AD: Alzheimer's disease PD: Parkinson's disease ASD: Autism spectrum disorder.</p></table-wrap-foot></table-wrap><table-wrap position="float" id="T2" orientation="portrait"><label>Table 2</label><caption><p>Clinical studies of Dex in the neuropsychiatric diseases.</p></caption><table frame="border" rules="all" width="100%"><thead><tr><th valign="middle" align="center" scope="col" rowspan="1" colspan="1">
<bold>Diseases</bold>
</th><th valign="middle" align="center" scope="col" rowspan="1" colspan="1">
<bold>Subjects</bold>
</th><th valign="middle" align="center" scope="col" rowspan="1" colspan="1">
<bold>Therapeutic Regimen (Dex)</bold>
</th><th valign="middle" align="center" scope="col" rowspan="1" colspan="1">
<bold>Main Findings</bold>
</th><th valign="middle" align="center" scope="col" rowspan="1" colspan="1">
<bold>References</bold>
</th></tr></thead><tbody><tr><td valign="middle" align="center" scope="row" rowspan="1" colspan="1">AD</td><td valign="middle" align="center" rowspan="1" colspan="1">AD patients</td><td valign="middle" align="center" rowspan="1" colspan="1">Sublingually;<break/>30 mcg, 60 mcg or 90 mcg;</td><td valign="middle" align="center" rowspan="1" colspan="1">The administration of Dex demonstrated a significant reduction in the agitation score among patients with AD, with 60 mcg being the most effective dosage.</td><td valign="middle" align="center" rowspan="1" colspan="1">[<xref rid="r62" ref-type="bibr">62</xref>]</td></tr><tr><td valign="middle" align="center" scope="row" rowspan="1" colspan="1">PD</td><td valign="middle" align="center" rowspan="1" colspan="1">PD patients</td><td valign="middle" align="center" rowspan="1" colspan="1">Continuous intravenous infusion at a dosage of 0.2~0.6 mcg kg<sup>-1</sup> h<sup>-1</sup></td><td valign="middle" align="center" rowspan="1" colspan="1">Dex decreased effectively involuntary movement during surgical procedures without interfering with nerve activity in DBS.</td><td valign="middle" align="center" rowspan="1" colspan="1">[<xref rid="r68" ref-type="bibr">68</xref>-<xref rid="r70" ref-type="bibr">70</xref>, <xref rid="r75" ref-type="bibr">75</xref>-<xref rid="r77" ref-type="bibr">77</xref>]</td></tr><tr><td valign="middle" align="center" scope="row" rowspan="1" colspan="1">Epilepsy</td><td valign="middle" align="center" rowspan="1" colspan="1">Epilepsy patients who are unable to cooperate</td><td valign="middle" align="center" rowspan="1" colspan="1">Intravenous or intranasal;<break/>2 mcg kg<sup>-1</sup></td><td valign="middle" align="center" rowspan="1" colspan="1">In the diagnosis and treatment of epilepsy, Dex exhibited effective sedation properties without impacting the electrical activity of the brain as observed in MEG and ECoG.</td><td valign="middle" align="center" rowspan="1" colspan="1">[<xref rid="r90" ref-type="bibr">90</xref>-<xref rid="r91" ref-type="bibr">91</xref>]</td></tr><tr><td valign="middle" align="center" scope="row" rowspan="1" colspan="1">Anxiety</td><td valign="middle" align="center" rowspan="1" colspan="1">Adults and children with preoperative anxiety</td><td valign="middle" align="center" rowspan="1" colspan="1">Intravenous (0.2~0.5 mcg kg<sup>-1</sup> or intranasal (1~3 mcg kg<sup>-1</sup>)</td><td valign="middle" align="center" rowspan="1" colspan="1">Dex reduced anxiety levels obviously both before and after surgery.</td><td valign="middle" align="center" rowspan="1" colspan="1">[<xref rid="r19" ref-type="bibr">19</xref>-<xref rid="r20" ref-type="bibr">20</xref>, <xref rid="r95" ref-type="bibr">95</xref>-<xref rid="r96" ref-type="bibr">96</xref>]</td></tr><tr><td valign="middle" align="center" scope="row" rowspan="1" colspan="1">Depressive disorders</td><td valign="middle" align="center" rowspan="1" colspan="1">Depressed patients and parturients</td><td valign="middle" align="center" rowspan="1" colspan="1">Intravenous (0.5 mcg kg<sup>-1</sup>) pre or post ECT</td><td valign="middle" align="center" rowspan="1" colspan="1">Dex augmented the antidepressant effects of ECT and demonstrated potential in preventing postpartum anxiety.</td><td valign="middle" align="center" rowspan="1" colspan="1">[<xref rid="r109" ref-type="bibr">109</xref>-<xref rid="r111" ref-type="bibr">111</xref>]</td></tr><tr><td valign="middle" align="center" scope="row" rowspan="1" colspan="1">Agitation</td><td valign="middle" align="center" rowspan="1" colspan="1">Schizophrenia and bipolar disorder patients</td><td valign="middle" align="center" rowspan="1" colspan="1">Sublingual;<break/>120 mcg or 180 mcg</td><td valign="middle" align="center" rowspan="1" colspan="1">The sublingual administration of Dex exhibited a significant reduction in 2-hour agitation scores.</td><td valign="middle" align="center" rowspan="1" colspan="1">[<xref rid="r115" ref-type="bibr">115</xref>]</td></tr><tr><td valign="middle" align="center" scope="row" rowspan="1" colspan="1">ASD</td><td valign="middle" align="center" rowspan="1" colspan="1">ASD patients</td><td valign="middle" align="center" rowspan="1" colspan="1">Intravenous;<break/>1~5 mcg kg<sup>-1</sup></td><td valign="middle" align="center" rowspan="1" colspan="1">Dex demonstrated effective sedation to facilitate necessary tests for individuals with ASD.</td><td valign="middle" align="center" rowspan="1" colspan="1">[<xref rid="r123" ref-type="bibr">123</xref>-<xref rid="r125" ref-type="bibr">125</xref>]</td></tr></tbody></table><table-wrap-foot><p><bold>Abbreviations</bold>: Dex: Dexmedetomidine AD: Alzheimer's disease PD: Parkinson's disease ASD: Autism spectrum disorder, ECT: Electroconvulsive therapy DBS: Deep brain stimulation MEG: Magnetoencephalography ECoG: Electrocorticography.</p></table-wrap-foot></table-wrap></floats-group></article></pmc-articleset>